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   Magnetic Resonance Imaging is one of the most used imaging techniques in 
structural anatomic clinical diagnostics.  
In 1946, Bloch and Purcell (Nobel Prizes 1952) independently discovered that 
the nuclei of different atoms absorbed electromagnetic radiation in the radiowaves 
frequency range; this phenomenon was named nuclear magnetic resonance (NMR). 
In 1970 Raymond Damadian discovered that the distribution of water in the human 
body is the key to obtain information about living organism, indeed he showed that 
NMR signals of tumours differed from those of normal tissues. In 1972 Lauterbur 
and Mansfield (Nobel Prizes in 2003) showed that NMR signals could be used to 
create two-dimensional maps of the density of nuclear spins in a medium, paving 
the way for imaging applications, immediately employed for anatomic and 
diagnostic purposes. This idea was further developed by Ernst (Nobel Prize in 
1991): in 1975 he proposed to encode spatial information through the use of 
magnetic field gradients and decode them using the Fourier transform of the 
recorded signal. In the same year Mansfield produced the first human NMR image.  
The current state of the art technology uses field gradients to create sub-
millimeter-thick slices, allowing the detailed acquisition of high resolution 2D and 
3D images. With the fundamental technology based on NMR, MRI uses 
radiofrequencies as the source of excitation and magnetic fields; both of them have 
been shown to have no detrimental effects on patients. As a noninvasive imaging 
tool MRI has the potential to be less harmful compared to other imaging modalities 
employed to acquire diagnostic images, such as computer tomography (CT), using 
X-rays as well as positron emission tomography (PET) and single-photon emission 
computed tomography (SPECT) relying on radioactive sources. Hence, MRI 
analysis can be reiterated on the same patient, with insignificant side effects in 
contrast to other imaging modalities whose reiteration is restricted by radiation-




1.1.2 Basic Principles of NMR1,2,3. 
 
Atomic nuclei are positively charged masses composed of protons and neutrons. 
They are characterized by a magnetic angular momentum, or spin. As electric 
charges in motion are associated with a magnetic field, the rotating atomic nucleus 
can be treated as a magnetic dipole. When these nuclei are placed in a magnetic 
field of high intensity (B0), they align along the direction of the lines of force of the 
field, i.e.: parallel (up - lower energy level) or antiparallel (down - higher energy 
level). There is a constant dynamic difference between the number of nuclei 
oriented up and down, which depends on the intensity of B0. The distribution of 






Nu number of nuclei at higher energy level; N1 number of nuclei at lower 
energy level; ΔE energy difference between the two levels; KB Bolzmann constant; 
T absolute temperature. 
In equilibrium conditions the lower energy level is slightly more populated and 
the sum of the overall magnetic moments give rise to a single resultant magnetic 
moment, the macroscopic magnetization (M0). 
The nuclei do not actually align directly with the direction of the magnetic field, 
but rather rotate around the axis of the magnetic field with a precession motion. 
The precession rate is indicated as Larmor frequency and represents the 
electromagnetic radiation frequency allowing the nucleus to absorb energy. The 







frequency is linearly dependent on the magnetic field intensity as described by the 
following equation: 
 
W0 = γ x B0 
Equation 2 
 
W0 is the precession frequency, γ is the gyromagnetic ratio of the nucleus and 
B0 is the strength of the magnetic field. 
 
The gyromagnetic ratio defines the ratio between the magnetic moment and the 
intrinsic spin angular momentum, characteristic of each nuclear species. This 
means that, for a given magnetic field intensity, different nuclei can be 
distinguished on the basis of their different resonance frequencies. If hydrogen 
atoms are then placed into a magnetic field (B0) the angular momentum splits in 
two possible orientations, either aligned with (+ ½ ) or against the magnetic field (- 
½ ). This can be calculated from Equation 3: 
 
m = (2I+1) 
Equation 3 
 
Where m is the magnetic quantum number, I = ½ for 1H nuclei. Additional 
nuclei used in MRI diagnostic applications include 13C, 19F and 23Na, all of them 
having I = ½. 
The distribution of the two energy states (±½) is defined by a Boltzmann 
distribution, with a larger population being aligned with the magnetic field, or in a 
lower energy state. The difference in energy state population is defined as a vector 
with the macroscopic magnetization defined as M0 along the (vertical) z axis, 
conventionally chosen as the magnetic field direction. Irradiation at the Larmor 




between the two populations of spin and causes the decrease of the resulting 
macroscopic magnetization along the z axis. M0 experience a deflection from the z 
axis towards the x or y axis of an angle (“pulse angle”), where the receiver is 
located to measure the energy released during the following relaxation process and 












The mathematical analysis of the FID by Fourier transform allows to pass from 
the time domain to the frequency domain, obtaining the NMR spectrum as it is 
normally known (signal intensity as a function of frequency).  
Relaxation occurs after the RF pulse is turned off. At this point the net 
magnetization has been flipped onto the x or y axis now starts to relax back to the 
resting state. Relaxation occurs through two mechanisms: 
• Relaxation leading to recovery of the longitudinal magnetization 
• Relaxation leading to the decay of transverse magnetization 
T1 or longitudinal relaxation time, is the time required for the macroscopic 
magnetization along the z axis to reach 63% of its equilibrium value, immediately 
after the cessation of the pulse. This occurs through the interaction of the excited 
1H nucleus with its surroundings to release energy. T1 changes with the intensity of 
B0.  




The second mechanism is spin-spin relaxation or transverse relaxation. After the 
RF pulse has aligned the M0 vector onto the x or y-axis the signals are bunched 
together in a coherent ensemble (phase coherence). The protons start to process and 
interact with other protons, leading to an overall phase decoherence that reduces 
the transverse magnetization. The parameter T2 is a measurement of how quickly 
the in-phase signals become out-of-phase. T2 is independent by B0. 
 
1.1.3 Magnetic Resonance Imaging (MRI)1,2,3. 
 
MRI is a diagnostic scanning technique based on principles of NMR. It 
measures the signal from the hydrogen nuclei of water, which is modified by the 
chemical environment. NMR spectroscopy measures the characteristics of any 
hydrogen nuclei depending on their position in the molecule. Instead of obtaining 
information about chemical shifts and coupling constants, MRI gives spatial 
distribution of the intensity of the water proton signal in the volume of the body. 
This signal intensity depends essentially on three factors: the density of proton 
spins in a given volume, the longitudinal and transverse relaxation times T1 and T2 
of these spins. Using different RF pulse sequences, image intensity can be 
weighted with respect to T1 or T2. 
The data to create an MR image is obtained in a series of steps. First, the tissue 
magnetization is excited using an RF pulse in the presence of a slice select 
gradient. The other two essential elements of the sequence are phase encoding and 
frequency encoding/read out, which are required to spatially localize the protons in 
the other two dimensions. Finally, after the data has been collected, the process is 
repeated for a series of phase encoding steps. 
The gradient echo sequence is the simplest type of MRI sequence. It consists of 




acquired at some characteristic time after the application of the excitation pulses 
and this is defined as the echo time TE.   
The spin echo sequence is made up of a series of events : 90° pulse – 180° 
rephasing pulse. Following a 90° RF pulse, the magnetization vector lies in the 
transverse plane. Due to dephasing phenomena, some spins slow down and others 
speed up. A 180° pulse is then applied to ‘flip’ the spin vectors so that the 
previously slower vectors are effectively precessing ahead of the previously faster 
ones. After a further time delay (equal to TE/2), a spin echo is formed. 
 
 
Figure 2: The spin-echo pulse sequence 
 
Figure 3: Signal decay in a spin-echo sequence  
 
If a further 180 degree pulse is applied at time TE/2 after the peak signal of the 
first spin echo, then a second spin echo signal will form at time TE after the first 




peak amplitude due to T2 dephasing which cannot be rephased by the 180 degree 
pulses. 
The signal intensity SI depends not only from T2, but also from the spin-lattice 
relaxation time T1 and the proton density ρ. In clinical diagnosis is very important 
to obtain  images which one of these contributes is prevalent, and this can be done  





With a low ratio (TR-TE) in the equation, the image is weighted on the T1, 
while TE and TR long increase the weight of T2. The combination of TR long and 
TE short emphasizes the importance of ρ (Image proton-density). 
In the scale of the contrast, by convention, the areas that generate a stronger is 
assigned to a light color, while lower intensity corresponds to a darker color. 
Accordingly areas of the sample with longer T1 are darker, while a transverse 
relaxation time longer leads to a lighter color.  
The spatial position of the nucleus is fundamental to generate an image of a 
patient. A magnetic field gradient is a variation in the magnetic field with respect to 
position. Therefore, the Larmor frequency of the protons will be different and will 
then determine a difference in chemical shift of the signals in the NMR spectrum.  
This difference in chemical shift depends on their physical separation and the 
strength of the field gradient, thus provides information on the spatial arrangement 
in the sample. If a single gradient is applied along the x axis are not obtained 
enough information to deduce the position in space of the nuclei, but if we rotate 
the gradient in three directions (x, y, z) we can locate in the three dimensions of 
space. 




























Accordingly, a large number of spectra of the sample are registered, by varying 
the direction of the gradients, thus obtaining various projections of the object under 
examination.  The projections obtained, are encoded in images through a technique 
known as “zeugmatography”. 
The tomographic imaging, producing NMR images of a slice of the human 
body. The slice is composed of several three-dimensional elements, volume element 
or voxels. While MR image are composed by bidimensional elements called 
picture elements or pixels. The intensity of the NMR signal of the corresponding 
voxel is displayed in pixels using a gray scale. The different shades of gray of a 
pixel can be expressed with a number and the numerical difference between two 
different signals defines quantitatively the contrast. The contrast between two 





Where Ia and Ib are the intensity of two adjacent pixels.  
 The contrast is the ability to discriminate two adjacent structures with different 
structural characteristics. Many pathological events determine an appreciable 
variation of these parameters, among which the longitudinal (T1) and transverse 
(T2) relaxation times of the water protons, thus allowing to recognize affected 
areas. Nevertheless, the difference arising from these variations may be too small 
and leading to a negligible contrast. To this purpose, the addition of a suitable 
“contrast agents” to the system analyzed is often useful to obtain an appreciable 
contrast.  
However sometimes insufficient contrast is observed, and, thus the use of 











contrast agent used in other clinical imaging studies as PET or SPECT, these are 
not themselves directly imaged but rather enhance contrast indirectly by affecting 
the nuclear magnetic relaxation times of the water protons in surrounding tissues. 
Contrast agents are currently used in diagnostics to enhance the image contrast and 
roughly 30% of all MR images employ some form of CA administered 
intravenously to the patient. 
 
1.1.4 Contrast Agents (CAs)3,4 
CAs can be classified in different ways, according to their various features, such     
as:  
1. effect on images 
2. magnetic properties 
3. biodistribution. 
 
1. Magnetic resonance CAs work by reducing the T1 and T2 relaxation times 
of nuclei in the target tissue, and are thus described as either T1 agents or T2 
agents depending on whether the relative reduction in relaxation times 
caused by the CA is greater for T1 or T2. According to the effect on T1 
agents or T2 CAs can be divided on: 
• Positive (predominant effect of T1 shortening)  
• Negative (predominant effect of T2 shortening)  
Positive CAs have a similar effect on the T1 and T2  
but, since the T1 of the tissue has a higher value of T2,  at low doses 
the predominant effect is the decrease of the T1. Globally, CAs 
positive results in a better signal / noise ratio and a higher intensity of 




Negative CAs act preferentially by shortening T2 and T2* (effective 
transverse relaxation time). T2-Weighted images give negative 
contrast, due to the predominant effect of T2 shortening.   
The classification of MR CAs as either T1 agents or T2 agents is not 
always accurate, since any CA that reduces T1 also reduces T2. However, 
any agent that reduces T2 does not necessarily reduce T1, at least at MRI 
field strengths. Whether the CA functions as a ‘T1 agent’ or ‘T2 agent’ 
depends on the imaging sequence used, the magnetic field strength, the 
size of the CA, and how the CA is compartimentalized in the tissue. 
 
2. CAs can also be classified according to their magnetic properties as 
paramagnetic or superparamagnetic  agents. 
• Metal ions with one or more unpaired electrons are paramagnetic, and 
therefore possess a permanent magnetic moment. Molecular motions 
cause random fluctuations in this dipolar magnetic interaction, reducing 
both the longitudinal T1 and the transverse T2 relaxation times of the 
water protons. However T2 in some tissues are relatively short, this 
effect can be almost irrelevant. Gadolinium (Gd(III)) and manganese 
(Mn(II)) are examples of paramagnetic ions which are used as MR CAs, 
because their physical properties are suitable for efficiently reducing the 
T1 and T2 proton relaxation times. 
• Supermagnetic agents consist of materials, such as iron oxides, in the 
form of colloids made up of nanoparticles (5-10 nm in diameter) in 
suspension, which are composed of very small crystallites containing 
several thousand magnetic ions. The superparamagnetic materials 
behaves similarly to paramagnetism, except that, instead of each 
individual atom being independently influenced by an external magnetic 
field, that the magnetic moment of the entire crystallite tends to align 




ions do not cancel out but are mutually aligned, and the crystallites have 
a permanent magnetic moment, which is very large in the presence of a 
magnetic field, much larger than that of a single paramagnetic ion. 
Superparamagnetic agents were initially developed as T2-agents, 
producing a dark area on MRI images resulting from their negative 
contrast effect. However, a new generation of these agents has also been 
reported to have excellent T1-enhancing properties. 
3. According to their biodistribution CAs can be divided as nonspecific agents 
and specific or target agents. 
• Non specific agents are those that do not interact with any type of 
cells. Those agents can be extracellular fluid (ECF) agents, low 
molecular weight extracellular complexes that equilibrate rapidly 
between intravascular and interstitial space and then are mainly 
excreted by the kidneys. After being intravenously injected, these 
agents leak rapidly from the blood pool into the interstitium with a 
distribution half-life of about 5 minutes and are cleared mainly by 
the kidneys with an elimination time of about 80 minutes. ECF 
agents are extensively used in body imaging applications. They 
provide increased enhacement and visualization of lesions, such 
tumors. They also shown great utility in MR angiography and are 
used for detection of many brain pathologies. High molecular weight 
blood pool agents (BPA), such as high generation dendrimers, which 
reside within the intravascular space and are slowly excreted via the 
kidneys and/or the liver, can be considered as non specific agents. 
BPA or intravascular agents are significantly larger in size than ECF 
and have higher r1 relaxivities. Their high molecular weight (>20 
kDa) prevents leakage into the interstitium and they remain in the 
intravascular system for a prolonged time compared with 




remains stable over one hour, as its mainly renal elimination 
requires the previous degradation of the macromolecule. This 
extends the imaging window from about 1 minute to about 1 hour. 
The blood pool CAs can be divided into several classes, according to 
their mechanism of action: 1) the noncovalent binding of low 
molecular weight Gd(III)- based complexes to human serum albumin 
(HAS), which is the most abundant plasma protein, prevents 
immediate leakage into the interstitial space; 2) systems based on 
polymers or liposomes, based on an increase in the size of CA 
molecule, which slows down leakage through endothelial pores; and 
3) systems based on particles involving a change in the route of 
elimination. 
• The specific or target agents can be considered in two groups: those 
that are passively directed to a particular type of cell, and those are 
actively target to a molecularly specific site target with an 
appropriate ligand. The first group includes organ-specific agents for 
liver (hepatobiliary), spleen, lymph nodes, bone marrow or brain, 
mainly on the basis of agent size and chemical structure. The second 
group includes agents witch target pathological processes or state, 
such as inflammation, atherosclerosis, angiogenesis, apoptosis and 
tumors. They are cell labeling CAs, as they work through 
recognition of specific molecular markers of those processes at the 
cell surface, such as cell-specific receptor or transport proteins, 
accumulate at those molecular sites, usually in the intracellular space 







 1.1.5 Complexes of paramagnetic ions 3,5,6,7,8. 
 
First of all, it is important introducing some fundamental parameters to better 
understand how a paramagnetic ion behaves as a contrast agent.  
The efficacy of the CA measured as the ability of its 1 mM solution to increase 
the relaxation rate of water protons is called relaxivity and indicate as r1,2.  
 Paramagnetic CA’s increase the signal intensity of the tissue containing them 
by increasing the longitudinal and/or transverse relaxation rates (1/T1 or 1/T2) 
using their unpaired electrons to facilitate spin transfer. The diamagnetic (1/T1,2d) 
and paramagnetic (1/T1,2p) contributions to the relaxation rates of such solutions 
are additive: 
1/ T1,2obs. = 1/ T1,2d + 1/ T1,2p 
Equation 7 
 
Where (1/T1,2)obs is the observed solvent relaxation rate and the subscripts “d” and 
“p” refer to diamagnetic and paramagnetic, respectively. 
     The paramagnetic contribution to the relaxation rate is linearly proportional to 
the concentration of the paramagnetic species:  
 
1/ T1,2obs. = 1/ T1,2d + r1,2 [M] 
Equation 8 
 
     Where M = paramagnetic substance, r1,2 = proton relaxivity (s-1mM-1). 
Relaxivity (r1,2) is then defined as the concentration-dependent increase in 





     The overall relaxivity can be correlated with a set of physico-chemical 
parameters, which characterize the complex structure and dynamics in solution, 
they are: 
• the number of inner-sphere water molecules directly coordinated to the 
paramagnetic centre q, 
• the residence time of the coordinated water molecule τM, 
• the rotational correlation time representing the molecular tumbling time 
of a complex  τR, 
• the distance between the metal ion and the proton r, 
• electronic relaxation time T1e 
  The relaxivity enhancement of water protons in aqueous solutions of 
paramagnetic complexes arises from time fluctuation of the dipolar coupling 
between the electron magnetic moment of the metal ion and the nuclear magnetic 
moment of the solvent nuclei. This magnetic field around the paramagnetic center 
vanishes rapidly with distance. Therefore, specific chemical interactions that bring 
the water protons into the immediate proximity of the metal ion play an important 
role in transmitting the paramagnetic effect towards the bulk solvent. This 
interaction is expressed with a model that considers two contributions: inner sphere 
(IS), due to water molecules present in number q in the coordination sites of the 
Figure 4 
Model of Gd(III)-based 





ion, and outer sphere (OS), which involves all the solvent molecules diffusing by 
the complex: 
 




Where R1obs is the measured relaxation rate  relaxation and R1W the rate of the 
solvent without the paramagnetic complex. 
The inner-sphere water protons then exchange with bulk solvent protons and this 
way the paramagnetic influence is propagated to the bulk. This mechanism is 
depicted as the inner-sphere contribution to the overall proton relaxivity. Solvent 
molecules of the bulk also experience the paramagnetic effect when they diffuse in 
the surroundings of the paramagnetic center. The effect of the random diffusion is 
defined as outher-sphere relaxation. 
For certain agents, solvent molecules that are not directly bound in the first 
coordination sphere may also remain in the proximity of the paramagnetic metal for 
a relatively long time, this relaxivity contribution originating from these 
interactions is called second-sphere relaxivity. 
 
Inner-sphere contribution 
The inner-sphere contribution to the overall proton relaxation rate enhancement 
result from chemical exchange of the coordinated water protons with the bulk, the 
latter being much more populated. The observed signal correspond to that of the 
free water. 
The relaxation of the bound water protons is governed by the dipole-dipole 
(DD) and scalar (SC), or contact, mechanism, where both are dependent on the 




reorientation of the nuclear spin-electron spin vector, by changes in the orientation 
of the electron spin (electron spin relaxation) and by water (proton) exchange.  
The relaxation rates of water protons related Ti,M are generally expressed by the 












Where S is the the electronic quantic spin number (Gd= 7/2), γI is the nuclear  
giromagnetic ratio, g is the electron g-factor, μB is the Bohr magneton,  ωS and ωI 
are the nuclear and electron Larmor frequencies, r is the distance between the 
electronic spin and nuclear spin, τc,I correlation time. 
      The scalar interaction remains unaffected by reorientation of the molecule and 
is only modulated by electron spin relaxation and water exchange. The contact 

























































































































































  Where A / h is the hyperfine or scalar coupling constant between the electron of 
the paramagnetic center and the proton of the coordinated water, and τei correlation 
time. 
 
Second and outher-sphere contribution 
This contribution accounts for about 40% of the relaxivity of monoaquo Gd(III) 
complexes and arises from the modulation of the dipolar interaction by diffusion of 
the solvent molecules next to the paramagnetic center. 
 This occurs by two mechanisms: second-sphere relaxation and outer-sphere 
relaxation. Second-sphere relaxation occurs when water molecules in the second 
coordination sphere (H-bonded to lone pairs on the carboxylate oxygen atoms), are 
relaxed via a dipolar mechanism. This is difficult to quantify since the number of 
second-sphere water molecules and the metal-H distance are unknown, and τm is 
very short and is the likely limiting parameter in determining T1m. 
Outer-sphere relaxation arises from the translational diffusion of water 
molecules close to the paramagnetic complex. 
Experimental evidence for the occurrence of this solvent/metal complex 
interaction is difficult to obtain and, in most cases, its consideration may only 
represent a negligible correction to the inner- and outer-sphere relaxivities in the 
traditional model. However, in several cases, a careful analysis of the relaxation 
rate of the solvent as a function of magnetic field, pH and temperature allowed the 
evaluation of this contribution and the extraction of more useful and correct 
information from the data analysis. 
 
Hydration number (q) 
Inner-sphere proton relaxivity is linearly proportional to the number of water 
molecules directly coordinated to the paramagnetic ion.  
The presence of CA influences a decrease of theoretical hydration number for 




molecules which would result in a proportionally high relaxation enhancement, but 
Gd(III) is toxic under physiological conditions and has a strong tendency to 
precipitate in the form of gadolinium-hydroxide. In fact, the thermodynamic and 
kinetic stabilities of the complex, which are guarantees of non-toxicity, can 
considerably decrease when more than one coordinated site is occupied by water. 
The hydration number of a complex can be assessed from X-ray structure 
analysis; nevertheless, it also has to be determined in solution as the solid state 
structures do not always correspond to the species present in solution. There are 
several methods for determination such as NMR (Dysprosium Induced Shift, DIS) 
luminescence or EPR spectroscopy.  
In all clinically utilized CAs, q = 1. Similarly, gadolinium(III) complexes of 
most octadentate DTPA and DOTA derivatives contain just one coordinated water 
molecule. 
 
The distance between the metal ion and the proton (r) 
The distance between the water proton and the unpaired electron spin, r, is a 
difficult parameter to measure and to control. According to modified Solomon-
Blømbergen equations (equations 10-11) a decrease of 0.1 Å  in the r distance 
corresponds to a 20% increase in inner-sphere proton relaxivity, while a decrease 
of 0.2 Å results in a much as 50% increase. In principle, two possibilities could be 
imagined to shorten the metal-H distance with the aim to increase the relaxivity. 
First, higher title angles between the plane of the bound water and the metal-O 
bond could be induced by hydrogen bonding of the coordinated water to an 
appropriate side group of the chelate, which could result in a significant decrease of 
the metal-proton distance. 
The second possibility for increasing relaxivity through changes in the metal-H 




Nevertheless the r values used in relaxivity analyses of paramagnetic complexes 
are in most cases only estimations, because the metal-coordinated water hydrogen 
distance is a difficult parameter to obtain experimentally.  
 
The residence time of the coordinated water molecule (τM)  
The residence lifetime of protons (τM) plays a dual role in determining proton 
relaxivity. It modulates the efficiency of chemical exchange from the inner-sphere 
of the metal to the bulk, and also it is contributes to the overall correlation time 
(τc), that governs the dipole-dipole interaction between the electron and nuclear 
spin. 
The exchange of coordinated water protons can occur in two ways: 
independently of the exchange of the entire water molecule on which it resides, or 
via the exchange of the water molecule itself. 
Around neutral pH, the overall proton exchange rate is generally equal to the 
exchange rate of the entire water molecules, while, on increasing the acidity or 
basicity of the solution, the proton exchange may become considerably faster than 
the water exchange due to acid-or base-catalyzed pathways. 
Generally the value of  τM is in the order of 10-6 ÷ 10-9 s, which means 
conditions of rapid exchange about the time scale considered (τM << T1M), with a 
somewhat reduced dependence τM (i.e. it is not generally a limiting factor in the 
relaxation process). 
The value of τM is very important in case of paramagnetic complexes bounded 
with a macromolecules, in fact this linking increase the lifetime of the coordinated 
water, until to obtain τM≅T1M, and then the exchange with the bulk water is slow 
and bringing an decrease of the relaxivity value. 
The rate of water exchange between an inner-sphere water molecule and the 
bulk can usually be estimated by 17O NMR by measuring the transverse relaxation 




It was also studied the mechanism by which water exchange occurs. There are 
two types of mechanisms: dissociative, it breaks the bond between the water 
molecule coordinated metal and later forms the bond with the new water molecule; 
associative, it forms a new bond between the complex and the water molecule so as 
to have a transition state that contains both the outgoing molecule that the incoming 
one. 
 
Rotational correlation time (τR) 
A parameter which allows a considerable increase in relaxivity for the 
paramagnetic complexes, is the rotational correlation time; in fact the relaxivity 
value increases with the increase of the rotational correlation time. 
The rotational correlation time describes the molecular mobility, in particular 
the rotational mobility of the paramagnetic complex. 
Values of short τR are associated with small molecules and with a round shape; 
on the contrary a long  τR is characteristic of molecules with an high molecular 
weight and with irregular shapes. 
In order to obtain an increase of rotational correlation time is possible to act in 
two different ways: leading  the complex in tissues with an high microviscosity, or 
linking the paramagnetic complex with a macromolecule.  
 
Electronic relaxation time T1e 
The relaxivity of a paramagnetic complex depends on the electronic relaxation 
time, closely related to the magnetic characteristics of the metal, and at a lower rate 
to the structure of the ligand. 
Paramagnetic metal ions show an effect which depends on the number of 
unpaired electrons in the ion. Paramagnetic ions of various transition metals like 
Fe3+, Mn2+ and rare earth metals of the lanthanide series like Gd3+, Dy3+ etc., have 
received great attention as magnetopharmaceuticals. The choice of Gd(III) would 




more subtle reason it performs so well. Two other lanthanide ions, dysprosium(III) 
and holmium(III), have larger magnetic moments (due to orbital contributions to 
electron angular momentum) than that of Gd(III), but the asymmetry of these 
electronic states leads to very rapid electron spin relaxation. The symmetric S-state 
of Gd(III) is a more hospitable environment for electron spins, leading to a much 
slower electronic relaxation rate. 






3d 4f Bohr 
magneton 
25 Mn2+ [Ar]3d54s0 ↑ ↑ ↑ ↑ ↑  5.9 
26 Fe3+ [Ar]3d54s0 ↑ ↑ ↑ ↑ ↑  5.9 
64 Gd3+ [Xe]4f76s0   ↑ ↑ ↑ ↑ ↑ 
↑ ↑ 
7.9 
Table 1: electronic configuration of some paramagnetic metals 
 
Gadolinium(III) chelates 
Gadolinium(III) chelates represent an important class of contrast agents for 
Magnetic Resonance Imaging (MRI). In the past two decades the use of gadolinium 
complexes of simple polyaminopolycarboxylic ligands as extracellular MRI 
contrast agents has become widespread. The main problem of the medical 
utilizations of heavy metal ions like the Gd(III) ion is a significant toxicity of their 
“free” (aqua-ion) form. Thus, for clinical use of gadolinium, it must be wrapped in 
a complex of high stability and, even more importantly, it must show a long-term 
resistance to a transmetallation/transchelation loss of the Gd(III) ion. It was proved 
that the endogenous metal ions Zn(II) and Ca(II) are them a in competitors and, 




than for the two cations.  The most important toxicological feature of the complex 
is the rate of decomplexation/transmetallation in comparison with the rate of 
excretion of the complex from the body. The requirements for in vivo stability 
suggest that kinetic stability, also called kinetic inertness, of the complexes could 
be as important as their thermodynamic stability. 
From the structural point of view, two main families of organic ligands have 
been developed: twelve membered tetraazamacrocyclic cyclen derivatives (cyclen 
= 1,4,7,10-tetraazacyclododecane) and acyclic triamines (diethylenetriamine 
derivatives) with several chelating side arms, affording an octadentate model of the 
ligands.  
The coordination number of the Gd(III) ion in these complexes is nine with the 
last coordination site occupied by a water molecule, which is crucial for the 
contrast enhancement mechanism. 
Therefore, some important parameters to be taken in exam when designing a 
new Gd3+ contrast agent are:  
• High stability. The injection of gram amounts of gadolinium into patients 
presents some potential toxicity problems which  requires strong metal 
complexation by the parent ligand. 
• Good water solubility and low osmolality of the solutions used clinically. 
Injection of relatively small volumes of a concentrated solutions of the 
metal complex is required.  
• High relaxivity. The dependence of the relaxivity on structural features 
of the paramagnetic compounds represent an  important area of research 











































































































































  Figure 5: Clinically used gadolinium contrast agents 
The first six complexes shown in Figure 5 act as nonspecific extracellular 
agents. Following intravascular injection, these compounds distribute rapidly 
between plasma and interstitial spaces and are ultimately eliminated through the 
renal route with half-lives of about 1.6 h. The remaining three DTPA derivatives, 
[Gd(EOB-DTPA)( H2O)]2-, MS-325, and [Gd-(BOPTA)(H2O)]2-, are designed 
specifically as targeted agents. The BOPTA comple is known to target the 
hepatobiliary system and acts as a liver imaging agent, while MS-325 interacts 






1.2.1 Bifunctional Chelating Agents (BFCAs) 
 
 
The labelling of biomolecules with metal ions of diagnostic or therapeutic 
interest is an important tool in medicine. 
Different metal ions are widely used in diagnostic and can be divided according 
to the techniques into they which are employed (Table 2).   
 
Technique Metal ions Examples 
MRI Gd3+, Mn2+ 
Gd-DTPA-BMA (Omniscan®) 
Approved for body imaging, MR 






Approved for  neuroendocrine 
tumor management.  
 
SPECT 
67Cu2+,67Ga3+, 90Y3+, 99mTc, 
111In3+ 
99mTc-exametazime (Ceretec®) 




Labelling of biomolecules with contrast agents is usually performed by directly 




Several examples of MRI CAs directly bound to biomolecules are reported in 
the literature: for example a progesterone-Gd(III) chelate conjugate designed to 
image progesterone receptors for early detection of hormone related cancers9, or 
gadolinium chelates conjugated to peptides, as in the case of an arginine octamer 
prepared by standard peptide synthesis techniques on solid-phase resins, coupled to 










































A different approach can be used for MRI CAs, relying on a reversible 
interaction of the CA with the desired biomolecule. This strategy is exemplified by 
MS-325 (Figure 7)11, a Gd3+-complex containing a diphenylcyclohexyl apolar 
residue, bound to the metal coordination cage through a phosphodiester group. The 
apolar residue shows a strong affinity for human serum albumin (HSA), tightly 
binding to one of the hydrophobic pockets of this globular transport protein. The 
binding to HSA allows to modify the biodistribution of the CA while the reversible 
nature of the interaction warrant its excretion by glomerular filtration.  
A similar approach was pursued with LipoAAZTA, where an aliphatic C17 
straight chain plays the role of a fatty acid and binds strongly but reversibly to the 











































Complexes of positron (64Cu2+, 68Ga3+) or gamma (90Y3+, 99mTc) emitting 
radionuclides are largely used in positron emission tomography (PET) or single 
photon emission computed tomography (SPECT) respectively, a DTPA derivative 
(Figura 8) linkage with an analog somatostatine peptide (OC), is a SPECT imaging 
agent approved for routine clinical use as a diagnostic agent for neuroendocrine 





































    Radionuclides are also employed in therapy, in particular in the treatment of 
cancer, and can be generate beta (90Y3+, 177Lu3+) or alpha (212Bi3+, 226Ac3+) 
particles14. Ibritumomab tiuxetan (Zevalin®) is a monoclonal antibody conjugated 
with the chelator tiuxetan, to which a radioactive isotope (90Y3+ or 111Y3+) is added. 
Tiuxetan is a modified version of DTPA whose carbon backbone contains 
additional isothiocyanatobenzyl and methyl groups.15 
For the most part, clinical contrast agents are not specifically targeted to a 
protein or receptor. The linkage between these biomolecules increases the 
molecular specificity and allows their delivery to particular sites of human body. 
The biomolecules employed, usually peptides or monoclonal antibodies, are able to 
target particular kinds of cells with high selectivity and affinity.  
For MRI agents, the detection limit for a single Gd(III) complex is in the low 
micromolar range, and it is often necessary to incorporate multiple complexes to 
enhance molecular relaxivity. Non-covalent protein binding and oligomerization 
often result in increased relaxivity per Gd ion, because largest molecules increase 
the rotational correlation time (τR). The most reliable and frequently applied 
method of linking the metal ion (the probe) to the biomolecule (the carrier) is by 
means of a bifunctional chelating agent (BFCA). 
Bifunctional chelating agents are defined as molecules containing two different 











The chelating unit is committed to the stable coordination of the chosen metal 




bond with suitable vectors, represented by biomolecules or simple organic 
compounds. 
In recent years, a large number of BFCAs have appeared in the literature, those 
based on a polyamino polycarboxylic ligand are particularly efficient (figure 10). 
The main reason for this is that they form highly stable complexes with a wide 
variety of metal ions, this means that the undesired in vivo release of the metal ion 
is avoided. 
BFCAs can be divided into two main categories: acyclic, such as those based on 
the ligands EDTA or DTPA, and macrocyclic, such as those based on the ligands 
DOTA or TETA. In general, the differences between these two classes are in the 
stability of complexes (macrocyclics are more stable than acyclics) but macrocyclic 
ligands are usually kinetically more inert during complexation, requiring longer 










































The choice of the right ligand is a crucial point in the design of the final 
conjugate and depends both on the metal ion to be complexed and the biomolecule 
to be labeled. 
The conjugation of a BFCA to the molecule of interest (the carrier) can be 
performed by means of the reactive functional group. The carboxylic group is the 
most used, since it can be easily activated to allow attack by an amino group 
present in antibody or in peptide. A huge number of functional groups are reported 
in the literature for this aims: symmetrical or mixed anhydrides and active esters 
(such as pentafluorophenyl, p-nitrophenyl and NHS-esters) isothiocyanate and 
maleimide are frequently used reactive groups.  
Another important parameter to consider in the design of new BFCAs is the 
linker (or spacer, the spacing unit between the probe and the functional group). The 
linker can increase the water solubility of the molecule (ex. PEG chain) or increase 
its lipophilicity (aliphatic chains, aromatic rings), affecting the pharmacokinetics 
and the biodistribution of the final molecule biodegradation and elimination can be 
increased by linkers that can be cleaved in vivo, such as particular peptide 
sequences, ester/amide groups and disulfide bonds. 
The list of bifunctional ligands reported in the scientific literature is very long as 
several and different chelating agents have been modified with additional reactive 
functional groups depending on the metal ion to be complexed and the specific 
application involved. The comprehensive treatment of BFCAs is beyond the scope 
of this thesis and may be found in dedicated reviews.16,17  
A selection of the BFCAs employed for the preparation of Gd-complexes for 
MRI applications will be discussed in order to introduce the experimental work 
performed in the PhD period, focusing on the DO3A platform (leading to DOTA-








The structure of AAZTA embodies a seven-
membered ring with two endocyclic and one 
exocyclic nitrogen atoms, carrying a total of four 
carboxymethyl side arms18. The corresponding 
Gd3+-complex is satisfactorily stable, either 
thermodynamically (logKf = 20.5),19 kinetically or 
with respect to transmetallation (table 2). The two 
coordinated water molecules ensure a high 
relaxivity (7.1 mM-1s-1), not quenched by bidentate 
anions such as lactate and phosphate as observed 




















K+ 1.3 --- La3+ 17.53 19.48 
Mg2+ 8.31 9.27 Nd3+ 19.41 21.6 
Ca2+ 12.76 10.75 Eu3+ 19.93 22.39 
Cu2+ 22.27a 23.4a Gd3+ 20.24 22.46 
Mn2+ 15.44 15.2 Dy3+ 20.39 22.82 
Ga3+ 22.18 24.3 Yb3+ 21.59 22.62 























The synthesis of AAZTA (Scheme 1) involves 4 synthetic steps with an overall 
50% yield; the easy synthetic access to this ligand, combined with the interesting 
proprieties of its paramagnetic complexes, prompted different groups to prepare 

























Scheme 1: Synthesis of AAZTA 
 
The synthetic access to AAZTA allows the reactive functional group to be 
positioned on the ring (especially on the quaternary carbon atom bearing the 
iminodiacetic moiety, i.e.: C-6) or on one of carboxymethyl lateral arms.  
The first BFCA of AAZTA was obtained introducing a functional group 
containing a hydroxyl group, spaced with one carbon atom from the ring 20. In this 
synthesis, nitromethane was substituted with 2-nitroethanol to give as a product of 
double nitro-Mannich reaction a new hydroxyl functional group (scheme 2). It has 
been demonstrated that is possible to obtain the product forming in situ 2-
nitroethanol through the Henry reaction by using nitromethane and an excess of 

































The hydroxyl group was also used to introduce a carboxylic group by reaction with 
succinic anhydride; alternatively the protected ligand was reacted with thionyl 
chloride to convert the hydroxymethyl group into a 6-chloromethyl derivate. In a 
third strategy, this compound was reacted with 4-nitrophenyl isocyanate  and after 















































These compounds were used to prepare lipid-based paramagnetic particles used 
for the cell labelling or conjugated with small biomolecules. In addition the 
isothyocianate derivate has been employed to synthesise multimeric/dendrimeric 
MRI contrast agents21,22,23,24. 
Other similar hydroxyl derivates were synthesized with a higher number of 
carbon atoms in the spacer 25, however the synthetic route is parallel to that shown 
in Scheme 2. 
It has been reported another BFCA AAZTA-like with an amine moiety as 
reactive group, bounded to the ring with a little spacer of three carbon atoms 
(Scheme 4) 26. This synthetic approach is recalls the strategy used for the 
previously reported derivatives, the key step being the double nitro-Mannich 



































A further modification of AAZTA skeleton was made using 6-nitrohexanoic 
acid for the condensation reaction, obtaining a derivate with a free carboxylic acid 
moiety27 (Scheme 5) This derivative was subsequently conjugated with dextran and 




































All these AAZTA-like BFCAs share the common synthetic pathway, relying on 
the double nitro-Mannich reaction of N,N’-dibenzylethylenediamine, 
paraformaldheyde and a suitable nitroalkane in order to build a 7-membered ring. 




perhydrodiazepine ring with aliphatic spacer chains of different lengths 
characterized by functional reactive groups located at the end and devised to be 
conjugated. 
Different  AAZTA-based BFCAs  were obtained by selective alkylation at one 
of the secondary amine groups with tert-buthyl α-bromoester carryng a protected 
functional group at ω; alkylation of the remaining amine groups with tBBA (= tert-
butyl bromoacetate) followed by deprotection of the reactive functional group gave 
























R=  (CH2)4NH2  
Scheme 6 
 
1.2.3 DO3A (1,4,7,10-tetraazacyclododecane-1,4,7-triacetic 
acid) 
DO3A is a heptadentate ligand composed by four 
macrocyclic nitrogen atoms and three carboxylates. 
This chelator can be easily derivatized  on the unique 
nitrogen on the macrocyclic ring, to obtain several 
other DO3A-like BFCAs.  
DO3A  form stable complexes with a large number 
of metal ion such as transition metal ions and 
lanthanides, leaving two coordinated sites free for the 
binding of water molecules and giving neutral 















lanthanides complexes and especially for the Gd3+ complex this means an 
improvement in the relaxivity value; nevertheless in vivo several bidentate anions 
such as carbonate or phosphate can displace the coordinated water molecules, 
quenching the relaxivity and preventing in this way its application as a MRI 
agent.30,31,32.  
 
The synthesis of DO3A can be performed in different ways, firstly by direct 
alkylation of cyclen with bromoacetic acid in DMF or DMAc with subsequently 
purification, by ion exchange chromatography, from DOTA33. A recent improved 
method for synthesized DO3A involves the alkylation of cyclen with tBBA in 
dimethyl acetamide with sodium acetate as a base. After 60 h  of reaction at room 
temperature the tri-t-butyl ester was obtained after crystallization with a 65% yield 



































Another synthetic pathway involves the trivalent protection of cyclen with 
dimethylformamide dimethylacetal to give a tricycloderivate, subsequently 
hydrolysed with 50% aqueous ethanol to mono-N-formylcyclen. Subsequently the 
product was alkylated with tBBA followed by the combined hydrolysis of tert-





   By alkylation of the secondary amino group of DO3A is possible to obtain a 
series of new BFCA-DO3A like.  A huge number of functional groups are 
introduced into the DO3A skeleton, with different kind of linkers, amino 
groups36,37, isothiocyanate38, thiol39, bromo40, vinylsulfone41 and squarate 





















































All these compounds were used in a wide variety of applications, for examples 
the derivativee with amino moiety was conjugated to fluorescein isothyocianate in 
order to obtain a dual probe for MRI and Optical Imaging. The Sm(III) complex of 
the thiol derivative was employed in a biodistribution study, while the vinylsulfone 
moiety was conjugated to humanized antibodies for PET imaging. In another 
example the free amino group of DO3A was functionalized with a squarate ester, 
the latter being reactive towards amines and used for the multisite labeling of poly-
L-lysines and poly-L-ornithines.43   
An interesting examples of DO3A derivative was generated using propargyl 
bromide as alkylating agent (Scheme 10). This compound can be easily and rapidly 
conjugated to peptides by a Huisgen cycloaddition44. Copper(I) catalyzed 
cycloaddition of this compound with azides, produced an octadentate complex 









































The introduction of a methylphosphinic acid moiety on the DO3A structure 
results in Gd(III) complexes that show a fast coordinated water exchange rate, 
which is close to optimal for low field application  (0,5-1,5 T)45. The reason for 
such a fast exchange rate can be found in the steric constraint imposed by the bulky 
phosphinate group on the water coordination site and possibly in the structuring of 
the second hydration sphere brought about by the phosphinate moiety. To take 
advantage of this favorable water exchange property, two Bifunctional 
monophosphinate DO3A-Like were prepared, bearing either a free carboxyl group 






















A DO3A-like ligand with a 2-mehylpyridine-N-oxide coordinating unit formed a 
Gd(III) complex with a remarkably fast water exchange rate47. A derivative with a 
free carboxylic available for functionalization was conjugated to a calix[4]arene 
platform.48 (Figure 13) 
  A different BFCA DO3A-like was obtained introducing an acylhydrazine 
moiety as shown in figure 13 and subsequently used to prepare acid labile 


















An interesting example of DO3A BFCA with a aniline as a functional group was 
reported50. This compound was also conjugated with a galactopyranosyl moiety, as 
a substrate of β-galactosidase, an expression-product of the report gene Lac-Z 
commonly co-administrated intracellulary with the subject-gene of gene-therapy 
studies. The synthetic pathway of this compound (scheme 11) is composed by three 
different alkylation steps with (R,S)-2-bromo-4-(4-nitrophenyl)butanoate, 
bromoethyl-β-D-galactopyranoside tetraacetate and tBBA. Consecutive carboxyl 
and hydroxyl group deprotections and catalytic hydrogenation of functional group 




















































1.2.4 DOTA Monoamide 
This class of chelating agents requires a separate systematic treatment. In fact, 
for the synthesis of DOTA monoamide BFCAs is possible to start from DOTA, for 
example activating one of the carboxyl groups as N-hydroxysuccinimide ester, or 
from DO3A by an alkylation of the secondary free amino group, or from cyclen by 
monoalkylation with a suitable N-substituted 2-haloacetamide as reported in 
Scheme 12. These approaches differ in the starting material, the number of steps, 
yields and ease of purification. The differences between these DOTA monoamide 
derivatives are related to the functional groups used to conjugated the probe to the 
vector of interest and to the linkers of various length, rigidity or hydrophylicity 
used to space the metal chelate from the biomolecule.  The distance between the 
DOTA coordination cage and the vector may strongly affect both the conjugation 



















































Scheme 12: Schematic representation of the various strategies used to prepare DOTA 
monoamides. a-b = via DOTA, c-d-e/c-l-o = via cyclen, f-g-h-i/f-m-e/f-n/f-g-o = via DO3A 
The major part of DOTA monoamides are synthesized starting from DO3A by 
alkylation on free secondary amino group. One strategy (path f,g,h,i) involves the 
use of one different protecting groups on the acetic pendant arms, as  benzyl 
esters51 or ethyl esters52,53 (Scheme 13) and after selective removal of the protecting 
group, it is possible to obtain a free carboxylic moiety able to be conjugated with 
















R = Bz or Et
Scheme 13 
 
Alkylation of DO3A t-butyl ester was also used to prepare BFCAs DOTA 
monoamides with different functional groups as amino, maleimido, hydroxyl and 
formyl54 as shown in Scheme 14. The synthesis of all the adducts share the same 
basic strategy. DO3A t-butyl ester was alkylated with a tailored bromoacetamide 
bearing either a protected amine or alcohol group. After deprotection of the side 
arm the amino derivates were converted to the maleimido derivate by reaction with 
7-exooxohimic anhydride under microwave irradiation. The alcohol derivates were 






















































































Variants with a free aromatic amine and with a thiol reactive methanethiosulfate 





















    Functionalization of DO3A t-butyl ester has been exploited introducing a spacer 
carrying a free terminal carboxylic group (Figure 15) which, after transformation 
into NHS ester, was coupled to glutamine. The resulting complex was tested “in 
vitro” on different tumor cell lines and “in vivo” on cancer prone transgenic mice to 






















Final interesting examples showed that increasing the length of the 
carboxyamide arm of Gd-DOTA monoamide from two to three carbons atom 
results in gadolinium complexes with a water exchange rate almost two orders of 




A DOTA monoamide with a terminal alkyne functionality, designed for Cu(I) 
mediated azide-alkyne cycloaddition has been prepared by alkylating DO3A t-butyl 





















1.2.5 HP-DO3A (10-(2-hydroxypropyl)-1,4,7,10 tetraaza-
cyclododecane-1,4,7-triacetic acid) 
HP-DO3A is an octadentate ligand composed by four macrocyclic nitrogen 
atoms, three carboxymethyl side arms and a 
hydroxypropyl moiety. Gd-HPDO3A 
(Prohance®, Bracco Imaging) is a non 
specific contrast agent for MRI, 
commercially available and widely 
employed in the clinical practice. This 
neutral complex shows an high 
thermodinamic stability (Log KF= 23.8) and 
kinetic inertness that ensures no significant 
release of Gd3+ ions in vivo. The relaxivity 
value of this complex is 3.7 mM-1s-1 in water 



















Complex q τ r (ps) r 1 mM-1s -1 
Gd-HPDO3A 1.3 ±0.1 57 3.7 ±0.1 
Gd-DOTA- 1.1±0.1 63 3.5 ±0.1 
Gd-DTPA2- 1.1±0.1 55 3.8 ±0.1 
Gd-DTPA-BMA 1.1±0.1 53 3.8 ±0.1 
Table 3: Comparison among some different clinically used Gd(III)-complexes. 
 
The synthesis of HP-DO3A, reported in Scheme 15, involves the reaction of 
cyclen with dimethylformamide dimethylacetal to give the tricycloderivative which 
was hydrolysed with 50% aqueous ethanol to mono-N-formylcyclen. Subsequently 
the product was alkylated with cloroacetic acid  and without any purification steps 






























In literature there are only few examples of BFCAs based on HP-DO3A 
structure. In a first report, two compounds with a free carboxylic group were 




different linkers were used to connect the coordinating cage and the functional 
group, in one case a diethylene glycol unit and in the other an aromatic moiety as 
shown in Scheme 16. These compounds were conjugated to peptide such as 
bombesin and oxytocin63. 
In the first synthetic route the hydrophilic diethylene glycol spacer, protected as 
a benzyl ester, was prepared by a Williamson reaction using bromoacetic acid. The 
oxidation of terminal alkene gave the corresponded epoxide. (tBu)3-DO3A was 
alkylated with the epoxide and subsequently the hydrogenolysis of benzyl ester 


























1) Na, THF, BrCH2COONa







A second HP-DO3A-based BFCA containing an aromatic spacer, was  
synthesized in a three steps starting from epibromohydrin and benzyl 4-
hydroxybenzoate. The resulting epoxide was reacted with (tBu)3-DO3A followed 










The last reported HPDO3A-based BFCA, endowed with a free amino moiety is 
shown in Scheme 18. This compound was synthesized by reaction of DO3A with  
N-Boc-1,2-epoxy-3-propylamine followed by removal of the Boc group and 
subsequent complexation with Gd(III)64. This compound was reacted with 2-
iminothiolane in order to be conjugated with an activate phospholipid, and included 
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2. Outline of the thesis 
The PhD research activity was devoted to develop new efficient preparative 
accesses to Bifunctional Chelating Agents (BFCAs) and to explore their potential 
application, with a specific focus on diagnostic imaging applications. 
BFCAs embody a metal chelating unit and a reactive functional group. The reactive 
functional group is used to conjugate the chelating unit to a task-specific molecule, 
the latter being represented by small organic molecules, biomolecules, 
macromolecules. The corresponding conjugate retains the metal-chelating ability 
and allows to use the corresponding metal complex in the devised task. BFCAs are 
usually prepared through lenghty multistep synthetic sequences: elaborated 
protection-deprotection strategies are needed in order to manage the large number 
of functional groups present in this family of molecules. As a result, few BFCAs 
are commercially available and only in limited amounts and at relatively expensive 
prices. 
The research activity of this PhD was focused on the development of novel BFCAs 
for lanthanide ions. Lanthanide (Ln3+) metal complexes are widely employed in 
several diagnostic and therapeutic applications, ranging from the clinically used 
Gd3+-based MRI contrast agents, to Eu3+-complexes for fluorescent optical 
imaging, to 166Ho3+-chelates for SPECT imaging. The importance of the 
conjugation of these complexes with biomolecules can be easily exemplified by 
Lutathera®, a clinically approved 177Lu3+-macrocyclic complex  covalently bound 
to a somatostatin analog (Octreotide®), and used in the treatment of metastatic 
gastro-entero-pancreatic neuroendocrine tumors. 
In the research period, two different activities were carried out and may be 
summarized as follows:  




In this section, three original BFCAs were designed and synthesized. The BFCAs 
are derived from ligands commonly employed for the coordination of lanthanide 
metal ions, namely AAZTA (6-Amino-6-methylperhydro-1,4-diazepine-
N,N’,N”,N”-tetracetic acid), HP-DO3A (10-(2-hydroxypropyl)-1,4,7,10 tetraaza-
cyclododecane-1,4,7-triacetic acid) and DOTAMA (1,4,7,10-




























The three cited ligands are formally modified by the introduction of a aliphatic side 
chain bearing a ω-carboxylic acid, the latter representing the reactive functional 
groups of the resulting BFCAs. 
The syntheses of these BFCAs rely on a common key step involving the selective 
hydrolysis of a methyl ester in the presence of several t-butyl esters. Hydrolytic 
enzymes were found to be most efficient for this transformation. 
2) Conjugation of a novel BFCA to a task-specific molecule and evaluation of the 
conjugated Gd3+-complexes as MRI contrast agent. 
The AAZTA-derived BFCA developed in the previous activity was directly 
employed for the preparation of a conjugate, where the chelating agent is linked 




























The reactive functional group of the AAZTA-derived BFCA was used to link a 
cholic acid derivative, the latter showing a strong affinity with serum albumin. The 
resulting conjugated ligand was employed for the preparation of a Gd3+-complex 
with improved diagnostic properties. Indeed, the reversible binding of this 
conjugate with serum albumin extend the plasmatic half-life of the MRI contrast 
agent, leading to better images of blood vessels and allowing the accurate  
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Summary 
Bifunctional chelating agents (BFCAs) combine the complexing properties of a 
multidentate ligand with the presence of a free reactive functional group, mainly 
devoted to conjugation purposes. BFCAs are generally prepared through multi-step 
syntheses and with extensive application of protection-deprotection strategies, due 
to the large number of functional groups involved. Hydrolytic enzymes, with their 
exquisite chemoselectivity, provived the best results in the preparation of three 
different BFCAs based on well known ligand platforms. 
 
Introduction 
Metal complexes are widely used in diagnostic and therapeutic applications. 
Paramagnetic complexes of Gd(III) are routinely used in clinical MRI,[1] while 
chelates of radioactive metal ions represent the active imaging agents in PET and 
SPECT,[2] or therapeutic agent in radiotherapy.[3] In addition, different luminescent 
complexes are employed in Optical Imaging.[4] The thermodynamic and kinetic 
stabilities of metal complexes in biological conditions is challenged through a 
careful design/choice of the ligand structure, satisfying the metal requirements for a 
stable coordination.  In addition, the structure of metal complexes needs to be 
modified for different application-related purposes such as: i) introduction of 
lipophilic/ hydrophilic residue to modulate solubility properties and/or to promote 
the inclusion in different formulations ii) targeting to a specific biologic target 





BiFuctional Chelating Agents (BFCA) combine the complexing properties of a 
multidentate ligand with the presence of a free reactive functional group, devoted 
to conjugation or tailoring purposes. Several BFCAs are commercially available, 
although their number is still limited if the wide variety of metal ions to be used is 
taken into account. BFCAs are generally prepared through multi-step synthesis and 
with extensive application to protection-deprotection strategies, due to the large 
number of fuctional groups involved.[5,6] 
In this article we describe the preparation of three selected  BFCAs (Scheme 1) 
through a chemoenzymatic approach. The exquisite chemoselectivity of hydrolytic 
enzymes is engaged to handle the significant number of functional groups of 
selected polyaminopolycarboxylic ligands. The choice of the ligand platforms falls 
on three chelating agents usually employed for lanthanide ions, mainly because 
LnIII ions are extensively used in different imaging/therapeutic techniques and due 
to our experience in the development of ligand platforms for LnIII ions.[7,8] All 
BFCAs share a remote carboxylic acid group, protected as a methyl ester during the 
synthesis and selectively removed by chemical or enzymatic hydrolysis. 
 






























The first BFCA (L1) is a derivative of the heptadentate ligand AAZTA (6-Amino-
6-methylperhydro-1,4-diazepine-N,N’,N”,N”-tetraacetic acid).[9] Starting from the 
first report of the formation of a promising Gd(III)-complex for MRI application, 
AAZTA rapidly gained popularity, with several derivatives reported to date and 
continuous efforts devoted to the development of bifunctional derivatives.[10-13] 
The second BFCA (L2) is a derivative of the macrocyclic ligand HP-DO3A, best 
known for its Gd-complex actually employed in clinical MRI as contrast agent 
under the brand name ProHance and used with other lanthanide ions for the 
development of CEST-MRI imaging procedures.[14] The same macrocyclic 12-
membered ring is at the base of the third BFCA (L3), built on the base structure of 
DOTA-monoamides (DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic 
acid), the latter widely represented in several of the above cited applications. 
 
 
Results and discussion 
Synthesis of protected BFCA’s agent 
Bifunctional derivatives of AAZTA usually bear the reactive functional groups on 
the carbon atom carrying the primary amine group (position 6 of the 6-
aminoperhydro-1,4-diazepine ring). This is due either to an easier synthetic access, 
as in the original synthesis this carbon atom derives from a suitable nitroalkane, or 
to stereochemical and steric considerations, as substituents placed in this position: 
i) retain the symmetry plane of the ligands, ii) circumvent the generation of 
stereocenters as would happen in any other ring or pendant arm position, iii) avoid 
any steric influence on the metal coordination sphere. 
The first BFCA L1 was obtained introducing on the AAZTA skeleton a C9-alkyl 



























































Scheme 2   Synthesis of L1. Reagents and conditions: (i) SOCl2, MeOH, r.t.; (ii) 
NaNO2, Urea, DMAc, 50°C, 24h; (iii) N,N-Dibenzylethylenediamine diacetate, 
(CH2O)n, PhMe/EtOH, Rfx; (iv) HCOONH4, Pd/C 10%, MeOH, Rfx; (v) 
BrCH2COOtBu, K2CO3, CH3CN. 
 
The preparation of L1 is depicted in Scheme 2 and starts from ω-bromoundecanoic 
acid 1. The carboxylic group is protected as methyl ester 2, then the halogen atom 
is substituted with a nitro group through a SN2 reaction with sodium nitrite in N,N-
dimethylacetamide in the presence of urea. The ω-nitroester 3 is used in the ring 
formation step, taking place through a double nitro-Mannich reaction with N,N’-
dibenzylethylenediamine and paraformaldehyde. Catalytic transfer hydrogenation 
with ammonium formate and Pd/C allowed the combined removal of the benzyl 
groups located on the endocyclic nitrogen atoms and the reduction of the nitro 
group, leading to the triaminoester 5. The amine groups were exhaustively 




powdered potassium carbonate, giving after chromatographic purification the 
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Scheme 3   Synthesis of L2 and L3. Reagents and conditions; (i) SOCl2, MeOH; 
(ii) MCPBA, CH2Cl2; (iii) BrCH2COBr, K2CO3, CH2Cl2/H2O; (iv)  DMAc, TEA; 




The syntheses of the macrocyclic BFCAs is reported in Scheme 3; their preparation 
relies on a common synthetic precursor, i.e.: DO3A-tBu3 (1,4,7,10-
tetraazacyclododecane-1,4,7-triacetate tri-t-butyl ester), either commercially 
available or conveniently prepared through literature procedure[15] and differing 
only in the preparation and installation of the side arms. 
The preparation of the HP-DO3A-derived BFCA L2 requires the alkylation of the 
secondary amine group of DO3A-tBu3 with the epoxyester 9, obtained in two steps 
from 10-undecenoic acid, to give the mixed ester precursor 11. 
The side arm of the DOTAMA (DOTA MonoAmide) BFCA L3 was prepared by 
esterification of 11-aminoundecanoic acid followed by N-bromoacetylation in 
Schotten-Baumann conditions to give the alkylating intermediate 14. Reaction of 
the latter with DO3A-tBu3 in acetonitrile in the presence of potassium carbonate  
provided the mixed ester precursor 15. 
 
The first step in each compounds were the protection of carboxylic acid moieties 
by methyl ester group 8-11. Compound 8 was treated with MCPBA  to give the 
corrispondig epoxide 9, alkylation of DO3A was carried out using triethylamine as 
a base to obtain the compound 15. Compound 12 was prepared by the alkylation 
with bromoacethybromide and the final alkylation of DO3A with compound 12, 





The protected BFCAs described in the previous section share the presence of 
carboxylic groups protected with different ester moieties, namely t-butyl ester on 
the carboxylic groups involved in metal coordination and methyl ester on the 
carboxylic acid intended for conjugation purposes. 




by a judicious choice of hydrolytic conditions. Nevertheless, a similar example of a 
mixed ester of DOTA[16] highlighted the difficulties in finding conditions that avoid 
side-reactions as hydrolysis of t-butyl esters and transesterification (when alcohols 
are used as (co)solvents) on these specific substrates. 
 Compounds 6,15,16 are then subjected to an extensive screening aimed at 
individuating optimal experimental conditions leading to the BFCAs L1-L3 in 
preparatively useful yields. In this work “classical” chemical hydrolysis was 
complemented and compared with enzymatic methods. The exquisite 
chemoselectivity of hydrolytic enzymes can be useful to obtain the desired 
selectivity in the removal of the methyl ester groups.[17] To the best of our 
knowledge, only one report of the use of hydrolytic enzymes on ethyl esters of 
chelating agents esters can be found in the literature,[18] but the extreme similarity 
of the homogenously esterified carboxyl group led either to incomplete reactions or 
to poor yields with macrocyclic substrates. Our substrates offer better conditions 
for the operativity of enzymes, presenting a single methyl ester located at the end 
of an aliphatic chain, strongly resembling the chemical environment of fatty acid 
esters. 
The screening of “chemical” hydrolysis includes two different hydroxides (LiOH, 
NaOH), an alkaline carbonate and an alkaline bicarbonate, sharing the same mixed 
solvent system 2-propanol/water 1:1. The screening of enzymes involves three 
lipases, i.e.: PPL, CCL and an immobilized CAL (Lipase B Candida Antarctica on 
immobead 150, recombinant from Aspergillus oryzae), all of them run in a mixed 
solvent system MTBE/phosphate buffer (KH2PO4/K2HPO4, 1M, pH 7.5). The 



















a  Isolated yields, corrected by 1H-NMR with internal standard (diphenylmethane). 
Table 1: Reaction times yields and conversion of different ligands. (*ligand found 
as a complex). 
 
The results of Table 1 show that potassium carbonate and sodium bicarbonate are 
completely ineffective with all substrates even after 48h. Better results are obtained 
with alkaline hydroxides, with nearly complete conversion after 4-8h, depending 
on the substrate, with the AAZTA precursor reacting generally faster than the 
macrocyclic derivatives. It is noteworthy that in these runs, the products of the 
hydrolysis are unavoidably plagued by the presence of variable amounts of the 
alkaline cation, strongly retained in the macrocyclic cavity, a phenomenon well 
known for DO3A and DOTA derivatives.[19] Small amount of byproducts arising 
from the unwanted hydrolysis of t-butyl groups, can be detected in the crude 
reaction mixture, too. 
The use of enzyme leads to different results. PPL provided clean reactions with all 
three substrates, reaching completion after 36-48h and with nearly quantitative 
yields. Lower performances were shown with CCL, where good results were 
obtained with substrate 15 after 48 h, while an incomplete conversion was obtained 
 6 → L1 15 → L2 16 → L3 
 Time (h) Yield (%)a Time (h) Yield (%)a Time (h) Yield (%)a 
NaOH 4 91* 4 92* 6 89* 
LiOH 4 90* 8 90* 6 88* 
K2CO3 >48 0 >48 0 >48 0 
NaHCO3 >48 0 >48 0 >48 0 
PPL 36 97 36 98 48 94 
CCL >48 0 48 87 48 63 




with the cognate ester 16 and no reaction at all was observed with the AAZTA 
derivative 6.  
Gratifyingly and quite unexpectedly, the best results are obtained with supported 
CAL: conversion was complete in 4-5 h with the three BFCA precursors, and 
nearly quantitative yields are obtained from a simpler workup. No evidence of the 
hydrolysis byproducts observed with NaOH and LiOH can be found in the reaction 
mixtures, leading on easy workup, even more facilitated by the heterogeneous 
nature of the catalyst, and finally to higher isolated yields.  
According to all these considerations, supported CAL in phosphate buffer/MTBE 
proved to be the best combination for the selective removal of methyl esters of 
mixed ester precursors of AAZTA-, HP-DO3A and DOTAMA-based BFCA. The 





The preparation of BFCAs usually requires multi-step synthetic approaches and 
complex protection-deprotection strategies. In this work, the synthesis of three 
different BFCAs, based on the AAZTA, HP-DO3A and DOTAMA ligands is 
reported. The efficiency and selectivity of enzymes (lipases) are successfully 
employed for the multigram preparation of these BFCAs, with the key step 
represented by the selective removal of a methyl ester group in the presence of 
multiple t-butyl ester groups. The enzymatic protocol is preferred to chemical 
hydrolysis, where alkaline hydroxides can reach comparable hydrolytic activities 
but with the drawback represented by the formation of unwanted byproducts. 










All chemicals reagents are obtained from Aldrich or Alfa-Aesar and used without 
further purification. 1H-NMR and 13C-NMR spectra are registered on a Jeol Eclipse 
ECP300 spectrometer at 300 MHz and 75.4 MHz, respectively. Mass spectra are 




Methyl 11-Bromoundecanoate (2). 11-Bromoundecanoic acid (1, 38.0 g, 0.14 
mol) is dissolved in 200 mL of methanol and thionyl chloride (16 mL, 0.21 mol) is 
slowly dropped into the reaction mixture, kept in a ice bath. After the addition the 
resulting solution is refluxed for 2 hours, then cooled and a solution of potassium 
carbonate 20% is added until pH>9. The methanol is removed under vacuum and 
the aqueous suspension extracted twice with dichloromethane. The organic extracts 
are dried over Na2SO4, filtered and evaporated yielding 2 as a light brown oil. 
(38.20 g, 98%). 1H NMR (300 MHz, CDCl3) δ (ppm): 1.26 (s, 10H, CH2), 1.39 
(bquint, J = 6.9 Hz, 2H, CH2), 1.58 (bquint, J = 7.0 Hz, 2H, CH2), 1.82 (quint, J = 
6.9 Hz, 2H, CH2), 2.27 (t, J = 7.5 Hz, 2H, CH2), 3.37 (t, J = 6.9 Hz, 2H, CH2), 3.63 
(s, 3H, CH3). 13C {1H} NMR (75.4 MHz, CDCl3) δ (ppm):  24.9 (CH2), 28.1 
(CH2), 28.7 (CH2), 29.1 (CH2), 29.2 (CH2), 29.3 (CH2), 29.4 (CH2), 32.8, (CH2), 
33.9 (CH2), 34.1 (CH2), 51.4 (CH3), 174.2 (C). MS (ESI+) calculated for: 
[C12H23BrO2+H]+  279.09-281.09, found 279.16-281.15. 
Methyl 11-Nitroundecanoate (3). Methyl ester 2 (38.17 g, 0,14 mol) is dissolved 
in 50 mL of N,N-dimethylacetamide and to this solution pholoroglucinol (22.05 g, 
0.14 mol) and sodium nitrite (18.88 g, 0.27 mol) are sequentially added. The 




extracted 3 times with petroleum ether and the upper phase collected and 
evaporated under vacuum. The crude product is purified by silica gel column 
chromatography (95/5 petroleum ether/ethyl acetate) to obtain 3 as a light yellow 
oil (18.1 g, 54%).1H NMR (300 MHz, CDCl3) δ (ppm): 1.27-1.32 (m, 12H, CH2), 
1.60 (bquint, J = 7.2 Hz, 2H, CH2), 1.99 (quint, J = 7.2 Hz, 2H, CH2), 2.29 (t, J = 
7.5 Hz, 2H, CH2), 3.68 (s, 3H, CH3), 4.36 (t, 2H, CH2). 13C {1H} NMR (75 MHz, 
CDCl3) δ (ppm):  24.9 (CH2), 26.2 (CH2), 27.4 (CH2), 28.8 (CH2), 29.1 (CH2), 
29.2 (CH2), 29.3 (CH2), 34,1 (CH2), 51.4 (CH3), 75.8 (CH2), 51.4 (CH2), 174.3 
(C). MS (ESI+) calculated for : [C12H23NO4+H]+  246.32, found 246.12.  
Compound 4.  A mixture of the nitroester 3 (18.0 g, 0.07 mol) and N,N-
dibenzylethylendiamine diacetate (31.7 g, 0.09 mol) in 1/1 toluene/ethanol (300 
mL) is brought to reflux with magnetic stirring until a clear solution was obtained. 
Paraformaldeyde (8.4 g, 0.28 mol) is then added in a single portion and heating was 
continued for additional 5 hours. The solvent is removed under  vacuum and the 
residue purified by silica gel column chromatography (95/5 petroleum ether/ethyl 
acetate) to obtain compound 4 as a yellow light oil (30.2 g, 85%). 1H NMR (300 
MHz, CDCl3) δ (ppm): 0.69-1.32 (m, 14H, CH2), 1.60 (bquint, J = 7.2 Hz, 2H, 
CH2), 1.59 (bquint, 2H, CH2), 2.29 (t, J = 7.5 Hz, 2H, CH2), 2.51-2.65 (m, 4H, 
(CH2), 2.95 (d, J = 14.1 Hz,  2H, CH2), 3.50 (d, J = 14.1 Hz,  2H, CH2), 3.57 (d, J 
= 12.9 Hz,  2H, CH2), 3.66 (s, 3H, CH3) 3.72 (d, J = 13.1 Hz,  2H, CH2), 7.19-7.37 
(m, 10H, ArH). 13C {1H} NMR (75 MHz, CDCl3) δ (ppm):  23.1, 25.0, 29.2, 29.3,  
29.33 29.34 (CH2), 34.17 (CH2), 37.1 (CH2), 51.4 (CH3), 58.8 (CH2), 61.9 (CH2), 
64.1 (CH2), 95.2 (C), 127.3, 128.3, 129.2, 139.3 (CH), 174.4  (C). MS (ESI+) 
calculated for: [C30H43N3O4+H]+ 510.33, found 510.15. 
Compound 5. Compound 4 (30.0 g, 0.059 mol) is dissolved in methanol (150 mL), 
and 10% Pd/C (3.0 g) is added under N2 atmosphere. Ammonium formate (36.1 g, 
0.60 mol) is added in small portion, and the reaction heated to 60°C for 2h. The 




reduced pressure. The crude product is redissolved in dichloromethane and 
repeatedly washed with a 1M NaOH solution and (25 mL x 4). The organic phase 
is dried over Na2SO4, and evaporated to obtain the triaminoester 5 as a light yellow  
oil  (17.05 g, 95%). 1H NMR (300 MHz, CDCl3) δ (ppm): 1.23 (bs, 14H, CH2), 
1.57 (bt, J = 6.7 Hz, 2H, CH2), 2.56 (t, J = 7.5 Hz, 2H, CH2), 2.70 (m, 4H, CH2), 
2.75-3.01 (m, 4H, CH2), 3.62 (s, 3H, CH3). 13C {1H} NMR (75 MHz, CDCl3) δ 
(ppm):  24,9 29.1, 29.2, 29.35,  29.36 30.3 (CH2), 34.0 (CH2), 39.4 (CH2), 51.0 
(CH2), 51.4 (CH3), 56.4 (C),  59.6 (CH2), 174.3 (C). MS (ESI+) calculated for : 
[C16H33N3O2+H]+  300.17, found 300.5. 
Compound 6. In a mixture of the triamine 5 (17.0 g, 0.056 mol) and potassium 
carbonate (46.45 g, 0.34 mol) in acetonitrile, t-butyl bromoacetate (41 mL, 0.28 
mol) is added dropwise. The reaction is stirred at room temperature overnight. The 
inorganic salts are removed by filtration on a Buchner funnel and the solvent 
removed under reduced pressure. The crude product is purified by silica gel column 
chromatography to obtain the mixed ester 6 as a light yellow oil. (23.4 g, 55%).  1H 
NMR (300 MHz, CDCl3) δ (ppm): 1.22-1.30 (m, 14H, CH2), 1.426 (s, 18H, (CH3), 
1.432 (s, 18H, (CH3) 1.60 (m, 2H, CH2), 2.28 (t, J = 7.5 Hz, 2H, CH2), 2.62 (d, 
2H, J = 14.4 Hz, (CH2), 2.621-2.68 (m, 2H, CH2), 2.72-2.80 (m, 2H, CH2), 2.98 
(d, 2H, J = 14.1 Hz, (CH2), 3.22 (bs, 4H, CH2), 3.62 (bs, 4H, CH2),  3.65 (s, 3H, 
CH3). 13C {1H} NMR (75 MHz, CDCl3) δ (ppm):  22.1 (CH2), 25.0,  (CH2), 28.2 
(CH3) 28.3 (CH3),  29.2, 29.3, 29.6, 30.5 (CH2), 34.14 (CH2), 37.6 (CH2), 51.4 
(CH3), 51.9 (CH2), 59.4 (CH2), 62.6 (CH2), 63.1 (C), (CH2), 65.4 (CH2),  80.2,  
(C), 80.7  (C), 170.9 (C), 172.9  (C), 174.3 (C). MS (ESI+) calculated for : 
[C40H73N3O10+H]+  756.32, found 756.5.  
Methyl 10-Undecenoate (8). 10-Undecenoic acid (16.0 g, 0.087 mol) is suspended 
in methanol (50 mL) and thionyl chloride (8.9 mL, 0.12 mol) is added dropwise 
(external ice bath for cooling is required to maintain T<10°C). The resulting 




potassium carbonate is added until pH>9, then methanol is evaporated under 
vacuum and the crude product extracted thrice with ethyl acetate (3x25mL). The 
combined organic extracts are dried over Na2SO4, filtered and evaporated yielding 
compound 8 as a light brown oil. (17.2 g, 99%).1H NMR (300 MHz, CDCl3) δ 
(ppm): 1.22-1.41 (m, 10H, CH2), 1.61 (quint, J = 7.0 Hz, 2H, CH2), 2.05 (quart, J = 
6.7 Hz, 2H, CH2), 2.29 (t, J = 7.5 Hz, 2H, CH2), 3.65 (s, 3H, CH3), 4.90-5.01 (m, 
2H, CH2), 5.79 (ddt,  , J1 = 6.9 Hz, , J2 = 9.9 Hz, , J3 = 17.1 Hz, 1H,  CH). 13C 
{1H} NMR (75 MHz, CDCl3) δ (ppm):  24.9, 28.1, 29.1, 29.17, 29.2, 29.4, 33.8, 
34.1 (CH2), 51.4 (CH3), 114.2 (CH2), 139.2 (CH), 174.2 (C). MS (ESI+) 
calculated for : [C12H22O2+H]+ 199.16, found 199.30. 
Compound 9. Methyl 10-undecenoate 8 (2.0 g, 0.010 mol) is dissolved in 20 mL 
of CH2Cl2 and 3-chloroperbenzoic acid (70%, 2.45 g, 0.010 mol) is added. The 
reaction is stirred at room temperature for for 3 hours. A white solid forms and is 
removed by filtration on a Buchner funnel. The filtrate is thoroughly washed with a 
5% aq. NaOH solution. The organic phase is dried over Na2SO4, filtered and 
evaporated to obtain 9 as a colourless oil. (2.11 g, 92%). 1H NMR (300 MHz, 
CDCl3) δ (ppm): 1.22-1.62 (m, 16H, CH2), 2.28 (t, J = 7.5 Hz, 2H, CH2), 2.44 (dd, 
J1 = 5.1 Hz, J2 = 2.6 Hz,  1H, CH2),  2.44 (dd, J1 = 5.0 Hz, J2 = 3.9 Hz,  1H, CH2), 
2.87 (m, 1H, CH), 3.64 (s, 3H, CH3). 13C {1H} NMR (75 MHz, CDCl3) δ (ppm):  
24.97, 25.9, 29.2, 29.4, 29.5, 32.5, 34.1 (CH2), 47.13 (CH2) 51.5 (CH3), 52.39 
(CH) 174.3 (C). MS (ESI+) calculated for: [C12H22O3+H]+  214.1, found 214.06. 
Compound 11. Triester 10 (1.0 g, 0.0019 mol) and the epoxyester 9 (447 mg, 
0.0021 mol) are dissolved in N,N-dimethylacetamide (5.0 mL) and the solution is 
refluxed for 36 hours. The reaction mixture is diluted with CH2Cl2 (20 mL), 
washed with H2O (4 x 20 mL) and brine (3 x20 mL), dried (Na2SO4), filtered and 
evaporated under vacuum. The crude product is purified by silica gel column 
chromatography (eluent CH2Cl2/MeOH/NH3 95/5/0.5) to obtain the mixed ester 15 




1.34 (m, 12H, CH2), 1.43 (s, 18H, (CH3), 1.44 (s, 9H, CH3), 1.59 (quint. J= 7.1 Hz, 
2H, CH2), 2.04-3.49 (br, 26 H, CH2), 2.27 (t, J = 7.5 Hz, 2H, CH2), 3.64 (s, 3H, 
CH3). 13C {1H} NMR (75 MHz, CDCl3) δ (ppm):  24.9 (CH2) 25.8 (CH2), 27.9 
(CH3), 28.2 (CH3), 29.1, 29.4, 29.8 34.1, 34.8 (CH2), 51.4 (CH3) 51.8 (CH2), 52.1 
(CH2), 52.3 (CH2), 53.7 (CH2), 55.9 (CH2), 56.8 (CH2), 61.5 (CH2),  68.1 (CH), 
80.7 (C), 80.8 (C),  170.9 (C), 171.1 (C), 174.1 (C). MS (ESI+) calculated for : 
[C38H72N4O9+Na]+  751.52, found 751.01. 
Methyl 11-Aminoundecanoate (13). 11-Aminoundecanoic acid (5.0 g, 0.025 mol) 
is suspended in methanol (25 mL) and then thionyl chloride (3.6 mL, 0.05 mol) is 
added dropwise (external ice bath for cooling is required to maintain T<10°C). The 
mixture is stirred at room temperature for 12 hours. A solution of aq. 20% 
potassium carbonate is added until pH>9, then methanol is evaporated under 
vacuum and the crude product is extracted with ethyl acetate (3x25mL), the organic 
phase dried (Na2SO4) and filtered. Removal of the solvent yielded the ester 11 as a 
light brown oil. (5.3 g, 98%). 1H NMR (300 MHz, CDCl3) δ (ppm): 1.21-1.38 (m, 
12H, CH2), 1.55 (bquint, J = 7.02 Hz, 2H, CH2), 1.68 (bquint, J = 7.1 Hz, 2H, 
CH2), 2.26 (t, J = 7.5 Hz, 2H, CH2), 2.9 (quart, J = 6.6 Hz, 2H, CH2), 3.63 (s, 3H, 
CH)3 7.25 (bs, 2H, NH2). 13C {1H} NMR (75 MHz, CDCl3) δ (ppm):  24.9, 26.6, 
28.2, 29.1, 29.2, 29.25, 29.4, 34.1, 40.2 (CH2), 51.5 (CH3), 174.4 (C). MS (ESI+) 
calculated for : [C12H25NO2+H]+  216.19, found 216.10.  
Compound 14. Ester 13 (5.2 g, 0.024 mol) is added to a biphasic mixture of 
CH2Cl2 (25 mL) and an aqueous solution containing potassium carbonate (13.2 g, 
0.096 mol, in 25 mL). Bromoacetyl bromide (3.1 mL, 0.036 mol) is added 
dropwise into the vigorously stirred biphasic mixture and the reaction run for 2 
hours. The two phases are separated and the organic layer washed with water 
(3x25mL) and brine (25 mL). The solvent is evaporated under reduced pressure to 
obtain the amidoester 12 as a light brown waxy solid. (7.3 g, 90%). 1H NMR (300 




CH2), 1.60 (bquint, J = 7.3 Hz, 2H, CH2), 2.29 (t, J = 7.4 Hz, 2H, CH2), 3.27 
(quart, J = 6.6 Hz, 2H, CH2), 3.65 (s, 3H, CH3),  3.88 (s, 2H, CH2) 6.51 (bs, 1H, 
NH). 13C {1H} NMR (75 MHz, CDCl3) δ (ppm):  24.9, 26.8, 29.1, 29.2, 29.27, 
29.3, 34.1, 40.3 (CH2), 51.4 (CH3), 165.5.2 (C), 174.4 (C). MS (ESI+) calculated 
for : [C14H26 BrNO3+H]+  336.11-338.11, found 336.02-338.03. 
Compound 15. The triester 10 (2.0 g, 3.8 mmol) and the bromoacetamide 14 (1.43 
g, 4.3 mmol) are dissolved in acetonitrile (25 mL) and to the resulting mixture 
triethylamine (749 µL, 5.7 mmol) is added. The mixture is refluxed for 36 hours. 
The solvent was removed under vacuum and the oily residue taken up in 
dichloromethane (25 mL), washed with H2O (4x20 mL) and brine (3x20 mL), 
dried (Na2SO4), filtered and evaporated under vacuum. The crude product was 
purified by silica gel column chromatography (eluent CH2Cl2/MeOH/NH3 
95/5/0.5) to obtain the BFCA precursor 16 as a light brown oil. (2.2, 75%). 1H 
NMR (300 MHz, CDCl3) δ (ppm): 1.11-1.27 (m, 16H, CH2), 1.33 (s, 9H, (CH3), 
1.34 (s, 18H, CH3), 1.46 (quint. J= 7.2 Hz, 2H, CH2)   2.18 (t, J = 7.5 Hz, 2H, 
CH2), 2.40-3.34 (br, 24H, CH2), 3.54 (s, 3H, CH3) 8.67 (m, 1H, NH). 13C {1H} 
NMR (75 MHz, CDCl3) δ (ppm):  24.9 (CH2) 25.8 (CH2), 27.9 (CH3), 28.0 (CH3), 
28.1, 28.2 29.2 29.5, 39.4 (CH2), 50.6 (CH3) 52.6 (CH2), 53.28 (CH2), 53.3 (CH2), 
55.7 (CH2), 55.8 (CH2), 56.6 (CH2), 81.7 (C), 81.8 (C),  169.8 (C), 170.0 (C), 
171.4 (C) 172.4 (C). MS (ESI+) calculated for : [C40H75N5O9+Na]+   792.56, 
found 792.05. 
General procedure for chemical hydrolyses. Methyl ester (6, 15, 16, 200 mg) is 
dissolved in a 2-propanol/water (1:1, 10.0 mL). The alkaline 
bicarbonate/carbonate/hydroxide (1.5 eq) is added in a single portion and the 
reaction stirred at room temperature for the reported time (Table 4). 2-Propanol is 
then evaporated under reduced pressure and the aqueous phase is washed with 
CH2Cl2 (3x5 mL). The organic solvent is dried (Na2SO4), filtered and evaporated 




General procedure for enzymatic hydrolyses. Methyl ester (6, 15, 16, 200 mg) is 
added to a suspension of lipase (60 mg,) in a mixture of 2.0 mL of phosphate buffer 
(1M, pH 7.5) and 8 mL of methyl t-butyl ether. The reaction mixture is stirred at 
room temperature for the reported time (Table 4). The lipase is removed by 
filtration on a Celite®, the filtrate concentrated and the aqueous phase extracted 
with CH2Cl2 (3x5 mL). The organic solvent is dried (Na2SO4), filtered and 
evaporated under vacuum to give the corresponding BFCA. 
Ligand 1. 1H NMR (300 MHz, CDCl3) δ (ppm): 1.22-1.30 (m, 14H, CH2), 1.41 (s, 
18H, (CH3), 1.42 (s, 18H, (CH3) 1.60 (m, 2H, CH2), 2.31 (t, J = 7.5 Hz, 2H, CH2), 
2.62 (d, 2H, J = 14.1 Hz, (CH2), 2.62-2.68 (m, 2H, CH2), 2.72-2.80 (m, 2H, CH2), 
2.98 (d, 2H, J = 14.4 Hz, (CH2), 3.22 (bs, 4H, CH2), 3.61 (bs, 4H, CH2). 13C {1H} 
NMR (75 MHz, CDCl3) δ (ppm):  22.0 (CH2), 24.7,  (CH2), 28.2 (CH3) 28.3 
(CH3),  29.0, 29.2, 29.4, 30.4 (CH2), 34.1 (CH2), 37.6 (CH2), 51.9 (CH2), 59.3 
(CH2), 62.5 (CH2), 63.0 (C), (CH2), 65.4 (CH2),  80.3, (C), 80.8 (C), 170.9 (C), 
173.0 (C), 179.0 (C). MS (ESI+) calculated for : [C39H71N3O10+H]+ 742.51, found 
742.78. 
Ligand 2. 1H NMR (300 MHz, CDCl3) δ (ppm): 1.18-1.31 (m, 14H, CH2), 1.40 (s, 
9H, (CH3), 1.41 (s, 18H, (CH3), 1.55 (quint. J= 7.1 Hz, 2H, CH2)   2.21 (t, J = 7.35 
Hz, 2H, CH2), 2.67-2.80 (m, 10H, CH2),  2.88 (m, 8H, CH2), 3.01-3.15 (m, 1H, 
CH), 3.25 (s, 4H CH2), 3.29-3.37 (m, 2H CH2 ). 13C {1H} NMR (75 MHz, CDCl3) 
δ (ppm):  25.3(CH2) 25.7 (CH2), 27.9 (CH3), 28.2 (CH3), 29.1, 29.2, 29.8 34.9, 
36.4 (CH2), 49.6 (CH2), 51.2 (CH2), 52.8 (CH2), 53.1 (CH2), 56.1  (CH2), 56.5 
(CH2), 59.7 (CH2), 65.8 (CH), 81.2 (C), 81.4 (C),  170.6 (C), 170.8 (C), 178.7 (C). 
MS (ESI+) calculated for : [C37H70N4O9+Na]+   737.53, found 737.70.  
Ligand 3. 1H NMR (300 MHz, CDCl3) δ (ppm): 1.18-1.35 (m, 16H, CH2), 1.44 (s, 
9H, (CH3), 145 (s, 18H, CH3), 1.6 (quint. J= 7.2 Hz, 2H, CH2)   2.18 (t, J = 7.5 Hz, 
2H, CH2), 2.75-2.88 (br, 18H, CH2),  3.20-3.31 (m, 6H, CH2). 13C {1H} NMR (75 




29.2 29.3 29.6, 28.7, 34.9, 39.5 (CH2), 50.6 (CH3) 52.6 (CH2), 53.28 (CH2), 53.3 
(CH2), 55.7 (CH2), 55.8 (CH2), 56.6 (CH2), 80.7 (C), 81.8 (C),  169.9 (C), 170.0 
(C), 170.4 (C) 177.3 (C). MS (ESI+) calculated for : [C39H73N5O9+Na]+  778.54, 
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4. Gd(CN-AAZTA-MADEC), an excellent 
agent for DCE-MRI studies on mice on 1T 
scanners 
F. Arena, D. L. Longo, L. Consolino, E. Gianolio, P. Minazzi, G. B. Giovenzana 
and S. Aime. 
 
Submitting to Molecular Imaging and Biology 
Introduction 
The advent of MI era has witnessed the introduction of MRI scanners operating at 
lower magnetic field strength than the complex (and expensive) systems that are 
found in the specialized MRS/MRI labs dedicated to “in vivo “studies. The need for 
seeing MRI as one of the complementary imaging techniques for multi-model 
studies has stimulated manufactory companies to consider the possibility of 
offering scanners based on permanent- or electro-magnets and characterized by a 
user-friendly, imaging acquisition made. It is expected that the availability of this 
new generation of MRI scanners1 will be a key-components together with compact 
PET/SPECT and Optical Imaging instruments of the “in vivo” Molecular Imaging 
Lab that will support many biology departments based on mice studies. 
In this context it appears quite reasonable that MRI scanners will be exploited also 
in the Dynamic Contrast Enhancement (DCE)2,3 modality as the last 25 years of 
MRI clinic studies has clearly demonstrated the important results may be obtained 
by the use of paramagnetic Gd-complexes. It is well established that the efficiency 
of a Gd(III) complex to enhance the relaxation rate of water proton depends on the 
structure of the complex, on the strength of the applied magnetic field  and on the 





Two key applications of Gd-based contrast agents appears of general applicability 
in the MRI study of mice models namely the visualization of the blood vessel 
network5 and the assessment of vascular permeability in the tumor regions6,7. The 
best results for both applications have been obtained by using a Gd(III) complex 
able to reversibly bind to Serum Albumin. The formation of supramolecular 
adducts between the paramagnetic complex and the serum protein has beneficial 
effects both on the attainable relaxation enhancement (particularly high at 0.5-1.5 
T)8 and on the “in vivo” distribution properties. 
This work compares the efficiency of three Gd-albumin binding contrast agents 
(two well established and one ‘ad hoc’ synthetized) as blood pool agents and as 




Chemistry: Commercially available reagents and solvents were purchased from 
Sigma-Aldrich or Alfa-Aesar and used without further purification. B22956/19 was 
obtained by Bracco Imaging spa. Reactions were monitored by TLC on Merck 
60F254 (0.25 mm) plates. Spot detection was carried out by staining with an 
alkaline KMnO4 solution or with the Dragendorff reagent. NMR spectra were 
recorded at 298K on a Jeol Eclipse ECP300 spectrometer operating at 7.05 T; 
chemical shifts (d) are given in ppm, coupling constants (J) in Hz. ESI mass spectra 
were recorded on ThermoFinnigan LCQ Deca XP-Plus and melting points 
(uncorrected) with a Stuart Scientific SMP3 apparatus. 
Conjugate 3-tBu4-Me: Compound 1 (14.0 g, 18.9 mmol) and methyl 3-
aminodeoxycholate (2, 8.50 g, 21.0 mmol) were dissolved in dichloromethane (100 
mL). N,N’-Dicyclohexylcarbodiimide (4.9 g, 23.7 mmol) and 4-
dimethylaminopyridine (0.46 g, 3.8 mmol) were added to the solution and sttirred 




filtration on a Buchner funnel and the filtrate evaporated under reduce pressure. 
The residue was submitted to chromatographic purification, obtaining the desired 
product as a white solid (13.6 g, 64%). M.p. 70°C. 1H NMR (CDCl3, 300 MHz): δ 
= 5.73 (d, J = 7.4 Hz, 1H), 4.11 (m, 1H), 3.92 (m, 1H), 3.60 (s, 3H), 3.57 (s, 4H), 
3.17 (s, 4H), 2.93 (d, J = 14.1 Hz, 2H), 2.76-2.54 (m, 4H), 2.58 (d, J = 14.1 Hz, 
2H), 2.36-0.95 (m, 43H), 1.385 (s, 18H), 1.382 (s, 18H), 0.91 (d, J = 6.4 Hz, 3H), 
0.90 (s, 3H), 0.62 (s, 3H); 13C NMR (CDCl3, 75.4 MHz): δ = 174.7 [C], 172.9 
[2xC], 172.3 [C], 170.9 [2xC], 80.7 [2xC], 80.2 [2xC], 73.0 [CH], 65.4 [CH2], 63.1 
[C], 62.6 [CH2], 59.3 [CH2], 52.0 [CH2], 51.5 [CH3], 48.9 [CH], 48.3 [CH], 47.3 
[CH], 46.5 [C], 45.1 [CH2], 38.1 [CH],  37.6 [CH2], 37.1 [CH2], 35.9 [CH], 35.1 
[CH], 34.7 [CH2], 34.0 [CH2], 33.0 [CH ], 31.2 [CH2], 31.1 [CH2], 31.0 [CH2], 
30.6 [CH2], 30.5 [CH2], 29.7 [CH2], 29.6 [CH2], 29.4 [CH2], 29.3 [CH2], 29.0 
[CH2], 28.3 [6xCH3], 28.2 [6xCH3], 27.5 [CH2], 26.7 [CH2], 25.9 [2xCH2], 25.7 
[CH2], 25.0 [CH2], 24.8 [CH2], 23.9 [CH/CH3], 23.7 [CH2], 22.1 [CH2], 17.4 
[CH3], 12.8 [CH2]; MS (ESI+): m/z calcd for C64H113N4O12 [M+H]+: 1129.84; 
found: 1129.93. 
Compound 3: Compound 3-tBu4-Me (13.5 g, 12.0 mmol) was dissolved in a 
mixture of 2-propanol (100 mL) and a solution of sodium hydroxide (1.23 g) in 
deionized water (370 mL). The reaction mixture was stirred at room temperature 
for 48h, then evaporated under reduce pressure. The residue was redissolved in 
dichloromethane (20 mL) and trifluoroacetic acid (25 mL) was added, stirring the 
resulting mixture at room temperature overnight. Volatiles were evaporated and the 
residue triturated and washed with acetone (50 mL), obtaining ligand L1 (10.5 g, 
98%). Mp 210-212.5 °C. 1H NMR (DMSO-d6, 300 MHz): δ = 7.35 (d, J = 6.7 Hz, 
1H), 3.97 (m, 1H), 3.80 (m, 1H), 3.63 (s, 4H), 3.53 (s, 4H), 3.11-2.93 (m, 4H), 3.03 
(d, J = 14.7 Hz, 2H), 2.98 (d, J = 14.7 Hz, 2H), 2.29-0.87 (m, H), 2.10 (t, J = 7.2 
Hz, 2H), 0.94 (d, J = 6.4 Hz, 3H), 0.91 (s, 3H), 0.63 (s, 3H). 13C NMR (DMSO-d6, 




[C], 61.9 [CH2], 59.8 [CH2], 55.7 [CH2], 52.3 [CH2], 48.3 [CH], 48.1 [CH], 47.0 
[CH], 46.8 [C/CH2], 45.1 [CH], 37.2 [CH], 36.3 [C/CH2], 36.2 [CH], 36.0 [CH], 
35.4 [CH], 34.8 [CH2], 33.8 [CH2], 33.1 [CH], 31.6 [CH2], 31.4 [CH2], 31.13 
[CH2], 31.06 [CH2], 30.3 [C/CH2], 29.5 [CH2], 29.4 [2xCH2], 29.3 [CH2], 29.2 
[CH2], 27.6 [CH2], 27.1 [CH2], 26.3 [CH2], 26.0 [CH2], 25.9 [CH2], 25.1 [CH2], 
24.9 [CH2], 24.0 [CH2], 23.8 [CH3], 23.0 [CH2], 17.6 [CH3], 13.0 [CH3]; MS 
(ESI): m/z calcd for C47H77N4O12 [M-H+]-: 889.55; found: 889.65. 
Gd-(3): compound 3 (9.0 mmol) was suspended in deionized water (30 mL) and 
freshly prepared Gd(OH)3 (9.0 mmol) was added. The opalescent suspension was 
stirred at 80°C until complete solution was obtained (∼32h), periodically checking 
the presence of free Gd(III) with Xylenol Orange. The solution was then filtered on 
0.25 μm filters and evaporated under reduced pressure. The crude product was 
redissolved in deionized water (10 mL) and precipitated with acetone (50 mL) (3 
times), then the solid was dried under vacuum to constant weight to obtain Gd-L1 
as a white powder (7.0 g).  
Water proton relaxivity measurements: The longitudinal water proton relaxation 
rates were measured by using a Stelar Spinmaster (Mede, Pavia, Italy) spectrometer 
operating at 0.47 T by the standard inversion-recovery technique (16 experiments, 
2 scans). A typical 90° pulse width was 3.5 ms and the reproducibility of the T1 
data was ±0.5%. The temperature was controlled with a Stelar VTC-91 air-flow 
heater equipped with a copper/constantan thermocouple (uncertainty ±0.1°C).  The 
proton 1/T1 NMRD profiles were measured over a continuum of magnetic field 
strength from 0.00024 to 0.47 T (corresponding to a 0.01–20 MHz proton Larmor 
frequency) on a Stelar field-cycling relaxometer. The relaxometer operates under 
complete computer control with an absolute uncertainty in 1/T1 of ±1%. Data 
points from 0.47 (20 MHz) to 1.7 T (70 MHz) were collected on a Stelar 





17O measurement: Variable-temperature 17O NMR measurements were recorded 
with a Bruker Avance 14T spectrometer equipped with a 5 mm probe using a D2O 
external lock. Experimental settings were as follows: spectral width 9000 Hz, 90° 
pulse width (14 μs), acquisition time 10 ms, 1024 scans and no sample spinning. 
Solutions containing 2.6% of the 17O isotope (Yeda, Israel) were used. The 
observed transverse relaxation rates (R02obs) were calculated from the signal width 
at half-height (∆ν1/2): 
                                R02obs=π∆ν1/2 
Binding to HSA: Binding parameters (the affinity constant KA, the number of 
equivalent and independent binding sites n and the relaxivity of supramolecular 
adduct r1b were determined using the proton relaxation enhancement (PRE) 
method. The method is based on  the titration of a fixed concentration of Gd-
complex with increasing concentrations of macromolecule that results in an 
increase of relaxation rate. The fitting of the obtained curve afford the value of KA 
and r1b.  
 
Pharmacokinetic Study: Plasma pharmacokinetics were assessed on male Balb/C 
mice (18-20 g; Charles River Laboratories, Calco, Italy). The animals were cared 
for under an approved protocol and the guidelines of our University Animal Care 
and Use Committee. A group of three mice were used for each contrast agent. The 
mice were anesthetized with an intraperitoneal injection of a mixture of ketamine 
(Bedford, OH, 90 mg/kg) and xylazine (St. Joseph, MO, 10 mg/kg). A heparinized 
catheter was inserted into the tail vein for administration of the contrast agent and 
blood sampling. The contrast agent was injected at a dose of 0.05 mmol Gd/kg 
body weight (b.w.). Blood samples (50-100 µL) were collected from the catheter 
before injection and at 5, 30,60, 120, 360 min after injection for a total of six time 




obtain plasma. The plasma was diluted with sterile water (Baxter) and the Gd 
content was determined by ICP-OES. A two-compartment pharmacokinetic model 
was used to analyze the data and calculate the pharmacokinetic parameters such as 
distribution and elimination half-lives (Td1/2, Te1/2) from the percentages of the 
initial blood concentration C0 with GraphPad Prism software (GraphPad, San 
Diego, CA, USA). 
 
Magnetic Resonance Angiography: A group of three male BALB/c mice 
weighing approximately 20 grams were used in contrast enhanced MR blood pool 
imaging for each agent. Mice were anesthetized by injecting a mixture of 
tiletamine/zolazepam (Zoletil 100; Virbac, Milan, Italy) 20 mg/kg and xylazine 
(Rompun; Bayer, Milan, Italy) 5 mg/kg and placed supine in a solenoid Tx/Rx coil 
with an inner diameter of 3.5 cm. The contrast agents were injected via a tail vein 
at a dose of 0.05 mmol Gd/kg.  
MR images were acquired before and at 2, 5, 15, 30, 45 and 60 min post-injection 
of the contrast agents on a 1T MRI Bruker IconTM system (Bruker BioSpin MRI, 
Ettlingen, Germany). A 35 mm TX/RX mouse solenoid whole body coil was used 
for both RF excitation and for MR signal reception. A 3D GRE fast low angle shot 
(FLASH) pulse sequence (TR 10 ms; TE 4.1 ms; flip angle 40°; FOV 80x40x40 
mm; MTX 192x156x156; NEX 2; temporal resolution 3 min 4 s per image) with an 
isotropic spatial resolution of 416 µm was used for image acquisition. Three 
dimensional maximum intensity projection (MIP) images were reconstructed using 
the ImageJ program (http://rsb.info.nih.gov/ij/) by subtracting pre-contrast to post-
contrast images. 
 
DCE-MRI in mice tumor model: The B16 human melanoma cancer cell line was 
cultured in DMEM medium with 2 mM L-glutamine and 10% FBS at 37°C in a 
humidified atmosphere of 5% CO2. The cells were allowed to grow to about 90% 




adjusted to 106 cells/ml containing approximately 2.0x105cells in 0.2 ml, were 
implanted subcutaneously in the flanks of C57/Bl6 mice. Each implantation 
generated a tumor. Tumor size reached 0.5–1.0 cm in diameter 10-20 days after cell 
implantation. 
Magnetic resonance images were acquired on anesthetized mice with an Aspect M2 
MRI System (Aspect Magnet Technologies Ltd., Netanya, Israel) working at 1 
Tesla. Mice were anesthetized by injecting a mixture of tiletamine/zolazepam 
(Zoletil 100; Virbac, Milan, Italy) 20 mg/kg and xylazine (Rompun; Bayer, Milan, 
Italy) 5 mg/kg and placed supine in a solenoid Tx/Rx coil with an inner diameter of 
3.5 cm. Breath rate was monitored throughout in vivo MRI experiments using a 
respiratory probe (SAII Instruments, Stony Brook, NY - USA). A phantom filled 
with diluted ProHance® (Bracco Imaging SpA, Milan, Italy) was included in the 
field of view (FOV), close to each animal, to allow correction for changes in the 
instrument performance. After the scout image acquisition, a T2-weighted (T2w) 
anatomical image was acquired with a Fast Spin Echo sequence (TR 2500 s; TE 41 
ms; number of slices 10; slice thickness 1.5 mm; FOV 40 mm; matrix 128 × 128; 
four averages; acquisition time 2 m 40 s).  
DCE–MRI was performed using an axial 2D T1w spoiled gradient echo sequence 
(TR 40 ms; TE 1.8 ms; flip angle 60°; number of slices 10; slice thickness 1.5 mm; 
FOV 40 mm; matrix 128 × 128; one acquisition; temporal resolution 58 s per 
image) with dynamic series was acquired with three initial pre-contrast T1w 
images and 47 dynamic post-contrast images for a total examination time of 50 
min. The contrast agents were injected intravenously at a dose of 0.05 and 0.025 
mmol Gd/kg. Three mice were used in each experimental group for each dose and 
for each blood-pool contrast agents.  
MR images were evaluated using in-house written software developed in Matlab 
(MathWorks, Natick, MA) and signal intensities (SI) of tumor, muscle and artery 
was measured in source images by drawing corresponding ROIs to evaluate SI 




ethics committee of our University and carried out in accordance with the EU 
guidelines. All animals were maintained under specific pathogen-free conditions 
inside the animal facility and received standard rodent chow and had free access to 
tap water. 
 
Results and Discussion 
Figure 1 reports the chemical structure of the three Gd(III) agents used in this 
work, namely MS-325 (Vasovist® or Ablavar®)11 (1), B22956/1(2)10 and Gd(CN-
AAZTA-MADEC) (3). The synthesis and the characterization of (1) and (2) were 
already reported. The third paramagnetic complex Gd-(3) is an original derivative 
of the ligand AAZTA (=1,4-bis(carboxymethyl)-6-[bis(carboxymethyl)]-amino-6-
methyl-1,4-diazepane)12 recently reported to show a good compromise between a 
higher metal hydration and a good thermodynamic and an excellent kinetic stability 
with lanthanides metal ions.13 The AAZTA ligand is formed by seven-member ring 
with two endocyclic and one exocyclic nitrogen atoms and four carboxymethyl side 
arms, representing an novel intermediate family between the open chain DTPA and 
the macrocyclic DOTA ligand. Gd-(AAZTA) shows a relaxivity value 65-70% 
higher than the congeners Gd-DTPA and Gd-DOTA, chiefly ascribed to the 
presence of the two rapidly exchanging coordinated water molecules (q = 2). 
Lipophilic derivatives of Gd-AAZTA where used to form non-covalent conjugates 
with serum albumin (HSA),14 reaching remarkably high relaxivity values, and with 
lipoproteins ( HDL),15 (LDL),16 taking advantages of their uptake for tumor cells 
visualization. In Gd-(3) the Gd-AAZTA substructure is linked to the 
aminodeoxycholic residue through an amide bond but with a longer spacer, 
represented by a C9 aliphatic chain. Gd(CN-AAZTA-MADEC) has been properly 












































































Synthesis: The synthesis of Gd-L1 is reported in Scheme 1 and starts from the 
protected bifunctional derivative 1,17 recently prepared through a chemo-enzymatic 
approach, and from the methyl ester of 3-aminodeoxycholic acid, the latter 






























































i) NaOH, i-PrOH, r.t.












 Scheme 1. Synthesis of Gd-L1. 
Standard amide coupling between 1 and 2 using DCC/DMAP in dichloromethane 
yields the protected conjugate 3-tBu4-Me; removal of the methyl ester and t-butyl 
ester groups is best obtained by a sequential combination of a mild alkaline 
hydrolysis (to avoid fission of the amide bond) followed by trifluoroacetic acid in 
dichloromethane, both performed at room temperature. The ligand L1 obtained is 





Relaxometric characterization of Gd complex: The complexation of the GdIII  
ion to the ligand CN-AAZTA-MADEC (3) was carried out by adding a 
stoichiometric amount of GdCl3 to the aqueous solution of the ligand at pH 7 and at 
room temperature. The presence of the aliphatic chain between the heptadentate 
ligand AAZTA and the deoxycholic acid moiety affects the relaxation enhancement 
properties of the Gd-(3).  The presence of the aliphatic chain induces the formation 
of self assembled aggregates above the millimolar concentration (Figure 2). 
 
Figure 2: Plot of variation of the observed longitudinal proton relaxation rate as a 
function of concentration of Gd-(3) at 21 MHz and 25 °C. 
 
The critical micellar concentration (cmc) of the system was conveniently 
determined by measuring the 1H relaxation rate as a function of the GdIII complex 
concentration. In general, titration of a ligand solution with GdIII ions leads to the 
formation of a paramagnetic complex; and a straight line for the relaxivity versus 
GdIII complex concentration plot is obtained [Eq.(1)], whose angular coefficient 
corresponds to the relaxivity  (r1p) of the complex, where R1w is the diamagnetic 





R1obs= [Gd-L] r1p + R1w           (1) 
In the case of Gd-(3) the sharp variation of the linear slope is observed when the 
system passes from monomeric state to micellar or self assembling systems. From 
the data reported in Figure 2, a cmc value of 1 mM was determined.  
At 20 MHz and 298K, the relaxivity of the Gd-(3) below the cmc is 13.9 mM-1s-1, 
whereas the relaxivity of the self assembled structure above the cmc is 20 mM-1s-1. 
The relaxivity of the non assembled form is about 35% higher than that of Gd-(2), 
as a consequence of the increasing in the molecular weight for the introduction of 
the relatively long aliphatic chain, as well as the introduction of the heptadentate 
ligand AAZTA with an inner-sphere water coordination number of 2. 
From the analysis of the temperature dependence of the transverse relaxation rate 
of the metal-bound 17O water resonance (Figure 3) we obtained a τM values of 100 
ns, a value that is similar than that reported for the parental complex Gd-AAZTA 
(90 ns)12 and for known Gd-(2) (120 ns), in the optimal range for the attainment of 
the high relaxivity in the presence of long molecular reorientational times.19 
 
Figure 3: Temperature dependence of the transverse 17O water relaxation rate (R2p) 




The effect of the aggregation may be evaluated by analyzing the profile of the 
relaxivity data as a function  of the applied field strength. The resulting plot of  
r1versus the Proton Larmor Frequency, named NMRD profile, for monomeric and 
aggregated systems measured at 298K and neutral pH is reported in Figure 4. 
Experimental data points were fitted on the basis of the Solomon-Blømbergen-
Morgan20 (for the inner sphere contribution) and Freed21 (for the outer sphere 
contribution) theories. Some fitting parameters were fixed to reasonable values: q 
and τM to the values obtained by 17O-NMR R2p analysis,  rGd-H  (distance for the 
inner-sphere water molecules) to 3.14 Å, d (distance of minimum approach 
between solvent and solute molecules) to 3.8 Å, and D (water diffusion  constant) 
to 2.2·10-5 cm2s-1. The obtained values for τR, Δ2 [square of the mean transient 
zero-field splitting(ZFS) energy], τV (correlation time for the collision- related 
modulation of the ZFS Hamiltonian) are reported in Table 1 and compared to those 
reported for the analogous Gd-AAZTA complex and to those of Gd-(2). The 
introduction of the deoxycholic  acid moiety in the DTPA derivative and in the 
heptacoordinated Gd-AAZTA derivative increases the molecular weight of the two 
systems, leading to a doubling of the reorientational correlation time value (τR).  
The aggregation of the complex additionally contributes to give a system with a 
slower molecular tumbling relative to the monomeric complex. The τR value 
reflects the increase in the size of the system due to the aggregation that involves 
the presence of 4-5 second sphere water molecules as a contribution to the NMRD 

























Figure 4: 1/T1 NMRD profile of 1 mM solution of Gd-(3), aggregated (●) and 
monomer (■) measured at 25°C. The solid curves through the data points were 
calculated using the parameters reported in Table 1. 
 
 









Gd-(3) monomer 13.9 3x1019 27 200 100 2 
Gd-(3) aggregates 20 3.2x1019 27 300 100 2+5 2nd sph. 
Gd-AAZTA 7.1 2.4x1019 31 70 90 2 
Gd-(2) 8.6 1.9x1019 41 173 120 1 
 
Table 1. Principal relaxometric parameters for the Gd-(3)-containing systems and 
related complexes, determined by NMRD and 17O-R2p-VT analysis. 
 
 


















Binding to HSA: In consideration of the possible use as an angiographic MRI 
system, the interaction with the human serum albumin (HSA) was investigated in 
detail for Gd-(3). The binding of Gd-(3)  to HSA was conveniently assessed by 
measuring the water proton relaxation rates of solutions containing the 
paramagnetic complex and by increasing concentrations of the serum protein (PRE 
method).22 With the estimation of the binding strength (nKA, where n is the number 
of binding sites) these measurement also provide a direct assessment of the 
relaxivity of the macromolecular adduct (r1b). Analysis of the relaxometric data 
obtained at 0.47T from the titration of a 60 μM aqueous solution of the GdIII 
complex with HSA at pH 7.4 and 298 K (Figure 5) allowed to determine the nKA 
and r1b values reported in Table 2. The binding affinity with HSA increase 
significantly, nKA value is one order of magnitude higher comparing with the Gd-
(2) adduct and the relaxivity of the noncovalently bound complex (r1b) is 38.7 mM-
















Figure 5: Plot of variation of observed longitudinal water proton relaxation rate of 
a 60 μM solution of Gd-(3) (■) and Gd-(2) (□) measured at 0.47 T and 25°C. 
 
 


















Contrast Agent nKA [104 M-1] r1b [mM-1 s-1] 
Gd-(3) 88.53±5.6 38.7±0.27 
Gd-(2) 4.78±1.77 27.7±0.68 
 
Table 2. Binding parameters for Gd-(3) and Gd-(2) systems, determined using the 
PRE method at 25°C in phosphate buffer solutions. 
 
The NMRD profile of Gd-(3)-HSA adduct was recorded in the range of 0.01-70 
MHz at 289K in phosphate buffer (Figure 6) to analyze the relaxometric 
parameters of the supramolecular adduct. The profile of the HSA adduct shows 
high relaxivity values at all fields, with a marked peak centered at 30 MHz, typical 
of slowly tumbling systems, and suggest that, upon binding to the protein, Gd-(3) 
maintains both the two inner sphere water molecules. 
 
 
Figure 6:1/T1 NMRD profile of 1 mM solution of Gd-(3) bound to HSA (■), Gd-





The data were fitted to the Lipari-Szabo model-free approach that takes into 
account the presence of an internal rotation, characterized by a correlation τRL, 
superimposed on a global motion described in term of the correlation time τRG.24 
The results are collected in Table 3and the fitting reveals a long global (whole 
adduct) rotational correlation time (τRG= 10 ns) and a short local rotational time 
(τRL=460 ps). 
     









Gd-(3) 13.9 3x1019 27                200 100 2 
  Gd-(3) + HSA 38.7 1.55x1019 15.4 TRL/[ps] 460 
TRG/[ps] 
10000 440 2 
Gd-(1) +HSA 40.2 2.4x1019 44 650 10000 183 1 
 
Table 3. Principal relaxometric parameters derived from the fitting of 1H-NMRD 
and 17OR2p profiles of Gd-(3) with/without HSA and comparison with Gd-(1). 
 
The order factor value S2 obtained from the fitting was founded to be 0.6, 
corresponding to a significantly flexible movements of Gd-(3) at the binding site. 
Surprisingly, the possible reduction in the exchange of the inner-sphere water 
molecules of Gd-(3) upon interaction with HSA,25 as already observed for the 
analysis of a similar Gd-AAZTA-bile acid conjugate,26 was not found for Gd-(3). 
The hydration number q = 2 was maintained, although the relaxivity values of the 
complex bound to HSA is far away from the maximum values predicted by theory. 
The principal reason could be correlated to the reasonable degree of local flexibility 
of this Gd-complex to the binding site, explaining the shorter τRL .The presence of 
a different rotational dynamics of the complex during the interaction with the 
protein plays against the achievement of relaxivity value suitable for a systems 




hydration number (q=2) of the complex following the interaction with HSA, the 
measurement of the 17O-VT R2p profile was performed. In order to ensure the 
complete formation of the HSA-Gd-(3) adduct, the profile was measured in a 
sample containing 3 mM Gd-(3) and 3 mM HSA. The analysis of the data reported 
in Figure 7, showed the high 17O NMR R2p values measured, along all the 
temperature range, for the HSA-bound complex compared to the free one. This 
observation confirms the possible conservation of two waters molecule in the 
inner-sphere even though the fitting of the 17O NMR data requires the presence of 
two species. A possible reason could be due to the coexistence of two difference 
structural isomers of the Gd-complex in solution, as can be seen from the 17O 
analysis. Despite the evidence of two isoforms of Gd-(3) in solution upon 
interaction with HSA, the hydration number q=2 was confirmed by the fitting the 
17O NMR data. 
 
Figure 7: Temperature dependence of the transverse 17O water relaxation rate (R2p) 




T). The curve through the data for HSA-bound Gd-complex was calculated for a 
model considering the presence in solution of two isomers. 
 
The long aliphatic chain likely allows the Gd-chelate to go away from potentially 
coordinating residues of the HSA protein, avoiding any interference with the 
exchange of the coordinated water molecule(s). The long aliphatic chain could be 
also responsible for the precise integration of the bile acid residue within the HSA 
binding site, defining the higher intensity in the binding affinity observed for this 
novel Gd-AAZTA-derivative. 
 
HSA binding sites: HSA has multiple binding sites, differing in their polarity as 
well as in the binding affinities towards hydrophilic and hydrophobic molecules. 
To shed more light on the binding interaction of Gd-(3) with HSA, binding assays 
with specific molecules like warfarin (site I) and ibuprofen (site II) are needed, as 
exemplified by the work of Sudlow et al.27 In a typical competition assay, a 
solution containing a Gd(III)-complex and HSA in a specified ratio undergoes a T1 
measurement (performed at 20 MHz and 298K) in the presence of increasing 
amounts of a molecule competing for a specific site. A decrease of the R10bs is a 
direct indication of the competition between the chelate and the added substrate. 
However, drug binding site I is as very large binding domain, with three distinct 
subdomains, which can accommodate simultaneously small-to-medium size 
molecules. This means that when probing the drug binding site I with warfarin, 
there is the possibility that it can still accommodate the Gd-complex molecule, 
without displacement of warfarin. For this reason, iodipamide, a larger molecule, 
was chosen to probe the interaction of the Gd-complex with the binding site I. The 





Figure 8: Variation of proton relaxation rates of aqueous solutions of 0.5 mM HSA 
and 0.05 mM of  Gd-(3), Gd-(2)  and Gd-(1) as a consequence of the competition 
for the binding to the protein upon addition of the substrate Iodipamide and 
Warfarin for the Site I and Ibuprofen for Site II ([Competitors]= 5 mM) . 
 
In Figure 8 the results for the competition-binding assay between Gd-(3) and two 
classical HSA binding substrates is reported and compared with the competition of 
Gd-(2) and Gd-(1). Only in the case of Iodipamide  (typical Sudlow’s site I ligand) 
a slight decrease in the R10bs is observed for Gd-(3), whereas no competition effect 
is obtained in the case of Ibuprofen (typical Sudlow’s site II ligand). A completely 
different behavior was observed in the case of Gd-(2) and Gd-(1). The general 
behavior of Gd-(2) is comparable with Gd-(3), with preferential interaction in the 
site II in which we can found a smaller variation in the T1 measures. The difference 
in the decrease of R10bs between Gd-(2) and Gd-(3) could be allocated in the 
difference in the binding affinity to HSA. Concerning Gd-(1), the favourite binding 
site was found to be site II, although the competition with Iodipamide shows some 
evidences of displacement, not shown in the previous work from Caravan11 when 
using the smaller molecule warfarin. It is likely that Gd-(1) binds primarily to site 




Comparison of NMRD profiles of Gd-(3), Gd-(2) and Gd-(1) in human and 
mouse serum 
As previously noted by Caravan et al,28 the binding and relaxometric properties of 
Gd-based “blood pool” agents may significantly change upon going from human to 
mouse serum albumin. Moreover human and mouse may differ in their 
composition and affect substantially the behavior of the paramagnetic complex in 
the two media. As these agents are intended for use in mouse models, a direct 
comparison of the NMRD profiles of the three complexes in human and mouse 






Figure 9: NMRD profile of Gd-(3), Gd-(2) and Gd-(1) in mouse (open square) and 






Contrast Agent Mouse Serum Human Serum R1p/mM-1s-1 
Gd-(3) 35.5 28.2 
Gd-(2) 22 20 
Gd-(1) 16.0 38.9 
 
Table 4: Relaxivities of Gd-(3), Gd-(2) and Gd-(1) measured at 1T and 37°C in 
mouse and human serum. 
 
The important evidence from the data reported could be summarized in the 
unrivaled behavior of Gd-(3) in both mouse and human serum,  not observed with 
Gd-(1) or Gd-(2). Gd-(1) shows a drastic difference in the bound relaxivities, as 
already reported by Caravan et al.,28 while for Gd-(2) the values are very similar 
but significantly lower than those of Gd-(3). The relaxivity of the non-covalently 
bound complex with Gd-(3) presents high values with respect to the other two 
complexes and allows this Gd-AAZTA derivative to represent the optimal Gd-
based blood pool agent for preclinical studies in both mouse models and in human. 
 
Pharmacokinetic Studies: The average plasma Gd concentrations calculated as 
percentage of the initial dose (C0) after a single bolus injection through the tail vein 
at a dose of 0.05 mmolGd/kg,  reveals a prolonged blood residence of Gd-(3) as 
compared to Gd-(2) and Gd-(1), over the entire period of the experiment (Figure 
10). The average plasma Gd concentration of Gd-(3) at 5 min post-injection was 
37.3% of the initial dose, while that of Gd-(2) and Gd-(1) was 29.9% and 24.2%, 
respectively. The blood concentration gradually decreased for all agents and at 6 h 
post-injection the plasma Gd concentration was less than 1%. The prolonged blood 
circulation time could possibly be explained by the higher binding affinity constant 
to HSA that in turn results in a reduced amount of the free from that is excreted by 




and a reduced renal filtration, as compared to Gd-(1), resulting in higher blood 
concentration values at all the investigated time points. The Gd plasma 
concentration profiles of the agents were analyzed with a two-compartment 
pharmacokinetic model. The mean values of half-life associated with the 
elimination phase, t1/2β, was longer for Gd-(3) (24.6 min) than for Gd-(1) (19.9 
min), and for Gd-(2) (18.2 min). The elimination half-lives of Gd-(2) and Gd-(1) 
were comparable to previous values obtained in rats.11,29,30 Considering that 
elimination half-lives in humans are six to nine fold longer than in mice, these 
results indicated that the order of magnitude of difference in the affinity constant of 
Gd-(3)-HSA may allow really steady-state MRI angiographic acquisitions. 
 
Figure 10: Plasma level decay as % of the initial dose (C0) after single intravenous 
injection of Gd-(3) (circles), Gd-(1) (triangles) and Gd-(2) (squares) at a dose of 
0.05 mmolGd/kg. Variability associated to each time/concentration point, 
expressed as standard deviations, ranged between 3 and 15%. 
Magnetic Resonance Angiography: Figure 11 shows the three-dimensional 




Gd-(2) and Gd-(1) at 2, 5, 15, 30 and 60 min post-injection of the contrast agents at 
a dose of 0.05 mmolGd/kg. The three investigated CAs showed different contrast 
enhancement properties, related to both duration and tissue localization. The Gd-(3) 
resulted in stronger and more prolonged contrast enhancement than Gd-(2) and Gd-
(1) in the heart and blood vessels. The visualization of vessels was enhanced up to 
30 min post-injection. Gd-(1) resulted in significant blood pool enhancement at 2 
min post-injection, with the signal that gradually fading away due to the clearance 
of the agent from the blood, resulting in a strong enhancement inside the bladder 
gradually increasing over time. Gd-(2) exhibited longer vascular enhancement 
duration than Gd-(1), but lower then Gd-(3). Gd-(2) also resulted in significant 
enhancement in the liver and gallbladder. 
The contrast enhancement pattern of the agents in the blood pool was consistent to 






Figure 11: Whole body coronal maximum intensity projection (MIP) of the 3D 
FLASH images obtained from the mice after intravenous injection of Gd-(3) (top), 
Gd-(1) (middle) and Gd-(2) (bottom) at a dose of 0.05 mmolGd/kg. Post-contrast 
images at 2, 5, 10, 15, 30, 45 and 60 min are shown here after the subtraction of the 
corresponding pre-contrast images. 
 
Figure 12 shows the normalized signal intensities in the heart, liver, urinary bladder 
and gallbladder relative to the signal intensity in muscle. The heart contrast 
enhancement was significant higher for Gd-(3) and Gd-(2) up to 30 min and 10 
min, respectively. 
 
Figure 12: Normalized signal intensity in the heart (A), liver (B), gallbladder (C), 
urinary bladder (D) (SI of heart, liver, gallbladder, urinary bladder / SI of muscle) 
before and at various time points post-injection of  Gd-(3) (circles), Gd-(1) 
(triangles) and Gd-(2) (squares) at a dose of 0.05 mmolGd/kg. Values are shown as 





Both Gd-(3) and Gd-(2) had a prolonged contrast enhancement in the blood pool as 
compared to the Gd-(1) CA. However, Gd-(3) resulted in clearer visualization of 
small blood vessels, providing effective contrast enhancement for more than 15 
min. The effective enhancement window of Gd-(3) in humans may be longer than 
in mice because the blood circulation in human is much slower than in mice. 
 
Vascular imaging requires both sufficient high relaxivity and long blood half life to 
obtain high contrast enhanced steady state images. To further investigates the 
marked vascular contrast enhancing properties between Gd-(3) and Gd-(2), despite 
their similar blood elimination kinetics, NMRD relaxivity studies with purified 
serum albumin from mouse and from human species were performed. Previous 
studies from Caravan et al. already showed species dependence on albumin 
binding.31  This dependence may bias the conclusions when comparing the results 
obtained in vitro at 25°C when using human serum albumin for clinical diagnostic 
applications with the results obtained in vivo at 37°C from their preclinical use in 
rodents. Therefore a blood pool CA designed and optimized for humans, may show 
sub-optimal relaxivity properties when used in other species. This is the situation 
for Gd-(1), whose outstanding relaxivity of ca. 39 mM-1s-1 in human serum (at 40 
MHz and 37°C) dramatically drops to 16 mM-1s-1 in mouse serum (Figure 9 and 
Table 4). Gd-(2) NMRD profiles were almost superimposable for both the two 
species, with r1pbound of 19 mM-1s-1 and 22mM-1s-1 for human and mouse serum, 
respectively. Therefore for this CA the interaction with the albumin from different 
species did not affect its relaxivity. On the other hand, the already high relaxivity 
shown by Gd-(3) in human serum (31 mM-1s-1) was even higher when added to the 
mouse serum (40 mM-1s-1). This marked species dependence of the investigated 
blood pool CAs explains the differences in contrast enhancement capabilities in the 
corresponding angiographic images. In fact, the longest elimination half-life, as 
well as the highest relaxivity showed by Gd-(3) in mouse serum resulted in the 




elimination half-life in comparison to Madec, it is not suited for mice angiographic 
images due to the low efficiency in mice serum. Gd-(2), despite having high 
relaxivity in mouse serum, resulted in angiographic images that are not optimal, 
due to the relative fast elimination kinetic and to the high liver uptake. 
 
Contrast Enhanced-MRI of tumor-bearing mice: All the CAs demonstrated to 
be able to induce a contrast enhancement inside tumors, exploiting the enhanced 
permeability retention effect, at the investigated doses of 0.05 mmolGd/kg. Figure 
13 shows the dynamic signal intensity enhancement in mice bearing B16 human 
melanoma xenografts, calculated inside the tumor tissue. Significant contrast 
enhancement was observed, already at 10 min post-inejction, for Gd-(3), Gd-(2) 
and Gd-(1), of 79.8%, 55.0% and 58.0%, respectively. The contrast enhancement 
slowly reduced thereafter for Gd-(2), being 44.5% at 30 min and 41.7% at 45 min, 
while for Gd-(3) and Gd-(1) remained constant along time (91.7% and 98.7% for 
Gd-(3) and 67.5% and 68.2% for Gd-(1), at 30 and 50 min, respectively). The 
tumor contrast enhancement of Gd-(3) was higher than that of Gd-(2) and Gd-(1)  
during all the dynamic acquisition series. The slow reduction of the contrast 
enhancement shown by Gd-(2) may be likely due to the accumulation of the 
contrast agent in the liver and gallbladder, thus resulting in a lower blood pool 
concentration along time, as reported by the pharmacokinetic profile, which turns 
in a reduced extravasation to the tumor region. On the contrary, the prolonged 
vascular retention for Gd-(3), allows a continue accumulation of the 
macromolecular adduct inside the tumor, thus resulting in a sustained and elevated 
contrast enhancement. In addition, we investigated the use of Gd-(3) for DCE-MRI 
approaches by halving the dose. Interestingly, the obtained contrast enhancement in 
tumor region was comparable with the enhancement reached by the Gd-(2) and Gd-





Figure 13: Signal intensity enhancement in tumor of mice before and at various 
time points post-injection of Gd-(3) (circles), Gd-(1) (triangles) and Gd-(2) 
(squares) at a dose of 0.05 mmolGd/kg and of Gd-(3) (diamond) at a dose of 0.025 
mmolGd/kg. Values are shown as mean ±SD (n=3) for each contrast agent. 
 
Conclusion 
A novel Gd(III)-based MRI contrast agent (Gd(CN-AAZTA-MADEC) optimized 
for preclinical DCE imaging application on mice, was designed and prepared. The 
contrast agent combines the excellent coordination proprieties of the AAZTA 
chelating at substructure with the HAS-binding ability of a cholic acid residue. 
The diagnostic potential of this novel CA was determined by comparison with two 
different CAs previously employed in DCE-MRI procedures. 
Gd-(3) shows superior relaxometric proprierties due to the higher hydration of Gd 
in the AAZTA coordinating environment. Relaxivities values became even higher 
in the presence of serum albumin, especially with mouse serum albumin where the 
relaxivity is significantly higher than HSA. The strong association with MSA/HSA 
leads to improved pharmacokinetic profiles with relevant advantages for DCE-




On the basis of the comparison among similar Gd-complexes for DCE-MRI, the 
newly developed Gd-(3) was shown to be the best contrast agent for preclinical 
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The research activity of the PhD has been focused on the development of novel 
Bifunctional Chelating Agents (BFCAs) and their applications in diagnostic 
imaging techniques. 
In the PhD period, different activities were undertaken… 
The first period of the PhD activity was dedicated to the design and the preparation 
of novel BFCAs. Chelating agents for lanthanide(III) ions were selected, because 
most diagnostic imaging techniques rely on the use of lanthanide(III) metal 
complexes as contrast agents or probes. Three well established ligand platforms 
were then chosen to prepare the corresponding BFCAs (i.e.: AAZTA, HP-DO3A 
and DOTAMA), and a synthetic strategy was devised in order to introduce a 
reactive functional group in a remote position of the chelating agent molecular 
backbone. To this purpose, an original chemoenzymatic approach was developed in 
order to manage the large number of functional groups associated with these 
polyaminopolycarboxyxlic molecules. The selectivity of hydrolytic enzymes was 
employed in the key step of the synthesis of the three BFCAs, leading to an 
efficient protocol used for their multi-gram scale preparation. 
The second part of the PhD activity took advantage of the availability of the 
BFCAs developed in the first period to prepare some conjugate chelating agents, 
whose metal complexes could be used in targeted imaging applications. In detail, 
the reactive functional group of the AAZTA-derived BFCA developed in the first 
year was employed to form a covalent link with a task-specific molecule (a cholic 
acid derivative). The resulting conjugate was used to prepare a Gd(III)-complex 




The relaxometric studies performed on this novel CA showed interesting results: its 
contrast efficiency is higher than that owned by similar CAs, either in water or in 
serum. Interestingly, the paramagnetic complex shows a relevant enhancement of 
its performances in mouse serum compared with human serum, due to a strong 
association with serum albumin. The pharmacokinetic of this novel CA is 
improved with respect to the compared CAs, and allows to obtain high quality 
images of blood vessels and to extract accurate structural and functional 
parameters. The species-specificity, combined with the fact that the best contrast 
efficiency is shown at low magnetic fields (0.5-1.5T) make this compound the best 
candidate for preclinical studies, where imaging of mice are routinely run on small 
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